
AI
Big Data
US-China Biopharma Congress 2017
SAPA-GP 15th Annual Conference
Winning for Patients
Building Global Pharmaceutical Ecosystems and Delivering Breakthrough Medicines
June 23-24, 2017
Sheraton Valley Forge Hotel
480 N Gulph Rd, King of Prussia, PA 19406
美中藥協
SAPA
Philadelphia 費城
www.sapa-gp.org
15th Anniversary

Greetings from Conference Co-Chairs

Dear SAPA-GP Members and Friends:

Welcome to 2017 Sino-American Pharmaceutical Professionals Association–Greater Philadelphia (SAPA-GP) Annual Conference. This year marks 15 years of continued growth of SAPA-GP in serving the scientific community and making a difference in building US-China biopharma connections. We are honored and proud to celebrate SAPA-GP's new milestone with you.

Staying true to our mission to promote in depth scientific discussion on cutting edge research, we organized a scientific symposium with the theme of "Battles against Old Foes: New Frontiers in Fighting Infectious Diseases" this year. Our speakers consisted of prestigious scientific leaders from both academia and industry who brought a memorable day to our audience in celebrating incredible scientific achievements in fighting infectious diseases and inspiring us to continue the long journey.

Nurturing the growth of our young and diverse talents is in the core of SAPA-GP's commitment. This year, we organized a Student Career Development Workshop at University of Pennsylvania, focusing on "Planning Career Development – Your Future Begins Now." This workshop attracted over 180 attendees from Pennsylvania, Delaware, New York, New Jersey and other states, and provided comprehensive information from landing the first job to future career development. To provide hands-on coaching, we renewed our mentor-mentee program and will continue to expand the program in the coming year to meet the high demand.

As a trusted partner, we have collaborated with leading biopharm organizations in China to co-organize and/or endorse conferences. We are privileged to build new relationships and strengthen our bonds with our long-term partners. Recently, we formed a strategic collaboration with Ascend, a leading PAN Ascend organization in the US, who provides industry-leading online learning tools to help our members in their journey of pursuing career success.

We also continued our collaborations with the Inclusion & Diversity Councils and Human Resources of multinational corporations and biotechs in the US and China to help them access the huge talent pool of SAPA-GP. You can access the frequently updated job postings at SAPA-GP online and at job fair sessions in the meetings and workshops we organized throughout the year, including this annual conference.

This year, we are proud to present to you a comprehensive conference program with discussions on cutting edge pharmaceutical research and transformational therapies, big data and artificial intelligence, the current regulatory environment, public private partnerships, CRO landscape, mergers and acquisitions, and business development. We also have a job fair and a session on career development. This one and a half day premier event will be attended by a large number of professionals and will provide a perfect platform for you to interact with leaders in the field, recruiters, human resource specialists, attorneys, entrepreneurs, investors, government officials, and peers to hear their expert perspectives.

We would like to take this opportunity to thank our leadership team and executive council members for their outstanding contributions. We also would like to express our eternal gratitude towards our sponsors, speakers, volunteers, friends and family members of SAPA-GP for their generosity and support. You made the success of SAPA-GP possible. We are not only adapting to the ever changing world; together we are changing the world!
Enjoy the conference!

Bin Shi, PhD
Conference Co-Chair
SAPA-GP President
Head of External R&D/Licensing
Amgen Asia R&D Center

Zhenhua Wu, PhD
Conference Co-Chair
SAPA-GP President-Elect
Associate Director
GlaxoSmithKline

15th SAPA-GP Annual Conference

Winning for Patients: Building Global Pharmaceutical Ecosystems & Delivering Breakthrough Medicines

June 23rd - 24th, 2017

Sheraton Valley Forge Hotel, 480 North Gulph Road, King of Prussia, PA 19406

Organized by: Sino-American Pharmaceutical Professionals Association - Greater Philadelphia

Organizing Committee

Yuchen Bai	David Cragin	Fenghao Chen	Haifeng Cui
Li Cui	Han Dai	Patrick Deng	Chengwei Fang
Tongming Fu	Meizhen Feng	Yu Gao	Yuanwei Gao
Dan He	Changhui Li	Gang Li	Xianhua Li
Yantao Li	Yufeng Li	Yutai Li	Xue Liang
Yin Liang	Nan Lin	Aston Liu	Yang Liu
Zhen Lu	Jiazhong Luo	Yangsi Ou	Fang Shen
Bin Shi	Jianting Shi	Mengjie Si	Yongchao Su
Hao Sun	Michael Tang	Weifeng Tang	Dan Tian
Hui Wang	Jim Wang	Lu Wang	Ying Wang
Yuefan Wang	Zhiyun Wen	Di Wu	Hao Wu
Shuang Wu	Zhenhua Wu	Chang Xu	John Xu
Ning Yan	Jing Yang	Hanghang Zhang	Jingyi Zhang
Jiayi Zhang	Ying Zhou		

Scientific Program Chair:	Jing Yang	Patrick Deng	Haifeng Cui	
Art Design:	Shuang Wu	Xianhua Li		
Brochure Editing:	Mengjie Si	Jianting Shi	Di Wu	Hao Wu

SAPA-GP History

The Greater Philadelphia area is one of the major homes for the world's pharmaceutical industry. It hosts more than half of the world's top-ten pharmaceutical companies, and many small/mid-size biotech companies as well as academic institutions. The Sino-American Pharmaceutical Professionals Association - Greater Philadelphia (SAPA-GP) was established in 2002 to serve the rapidly growing pharmaceutical/biotech/healthcare community in the GP area.

SAPA-GP Mission

To promote pharmaceutical sciences and biotechnology

To contribute to public health education by raising public awareness

To facilitate scientific and business cooperation between US and China

To foster career development of pharmaceutical professionals

2016-2017 SAPA-GP Events and Accomplishments

2016/04/06	Opened SAPA-GP Wechat Groups with More than 1500 Followers
2016/09/24	Organized a Student Career Development Workshop at University of Pennsylvania, Philadelphia, PA
2016/10/21	Hosted Visit by Shanghai Bioforum Delegation
2016/12/03	Organized the scientific symposium "Battles Against Old Foes: New Frontiers in Fighting Infectious Diseases" at Radnor Valley Country Club in Villanova, PA
2017/01/01	Initiated one to one Mentor-Mentee Program
2017/02/10	Hosted visit by Hubei Province Delegation
2017/04/07	Signed the collaboration memo with Pingyuan New District at the 2nd China Pharmaceutical Innovation & Development Summit at Hualan Industry Park in Xinxiang, Henan, China
2017/04/26	Co-sponsored the Precision Medicine and Immuno-oncology 2017 in Shanghai, China
2017/05/21	Co-organized DIA China 9th Annual Meeting at Beijing, China
2017/05/27	Organized Summer Picnic at Peace Valley Park, PA
2017/05/31	Hosted visit by Beijing E-town Delegation
2017/06/23-24	Organized SAPA-GP 15th Annual Conference at Sheraton Valley Forge Hotel at King of Prussia, PA

Program at a Glance

June 23, 2017, Friday

<table>
<tr><td>1:30-2:00 PM
Grand Ballroom</td><td colspan="4">Featured Presentation:
Delivering Cell and Gene Therapy: One Big Pharma's Approach</td></tr>
<tr><td>2:15-3:45 PM
Plenary Session I:
Big Data and Artificial Intelligence: Emerging Paradigm to Accelerate Delivery of Transformational Therapies
Grand Ballroom</td><td rowspan="2">2:00-5:00 PM
Job Fair & Onsite Interview
Centennial Ballroom I</td><td rowspan="2">2:30-4:30 PM
VIP Session A
CEO Forum: Innovative Drug R&D in China
Frazer</td><td rowspan="2">2:15-5:00 PM
VIP Session B
US-China Public Private Partnership (PPP): Biopharma Development Zones, Technology Transfer and Government Affairs
Centennial Ballroom III</td><td rowspan="2">2:15-5:00 PM
VIP Session C
US-China CRO Landscape: Building Success with Strategic Alliances
Haverford</td></tr>
<tr><td>4:00-5:15 PM
Workshop I:
Position Yourself for the Future – Power Plan for Success
Centennial Ballroom II</td></tr>
<tr><td>5:00-6:00 PM</td><td colspan="4">Networking</td></tr>
<tr><td>6:00-9:30 PM
Grand Ballroom</td><td colspan="4">Gala Dinner
Special Remarks: Jijun Xing, PhD, Science and Technology Counselor, Chinese Consulate-General in New York
Guest Presentation: Dengxi Wang, Deputy Secretary, CPC Xinxiang Municipal Committee and Mayor, Xinxiang Municipal People's Government</td></tr>
</table>

June 24, 2017, Saturday

8:35-9:25 AM
Grand Ballroom

Featured Presentation:
Kelun- Scientific Truth- Seeking, Ethics for Good Situation and Present Policies of China's Pharmaceutical Industry

9:30-10:30 AM **Plenary Session II:** **Innovative Medicines: Transforming Patient Care** *Grand Ballroom*		**9:30-12:00 PM** **VIP Session D** **Pharma/Healthcare Global Deal Dynamics forum** *Haverford*	**9:30-12:00 PM** **VIP Session E** **SAPA-Hopkins Venture Forum** *Centennial Ballroom I*
10:45 AM-12:15 PM **Workshop II:** **Regulatory and Market Access** *Centennial Ballroom III*	**10:45 AM-11:45 PM** **Workshop III:** **Perspectives of Biopharma R&D in China** *Centennial Ballroom II*		
12:15-1:15 PM Lunch Sessions I to IV			
Lunch Session I: **Aiming for Success: Biotechnology Entrepreneurship Boot Camp** *Ardmore*	**Lunch Session II:** **Six Key Successful Retirement Strategies** *Paoli*	**Lunch Session III:** **Executive Development Programs: A Gateway to Leadership Excellence** *Frazer*	**Lunch Session IV:** **Latest Developments in PIV Litigation and New Opportunities for Obtaining Generic Exclusivity** *Devon*
1:30-3:30 PM Workshops IV to VI			**1:30-3:30 PM** **VIP Session E** **SAPA-Hopkins Venture Forum (Con.)** *Centennial Ballroom I*
Workshop IV: **Navigating through the Changing Regulatory Environment** *Centennial Ballroom III*	**Workshop V:** **Biosimilar Development: Strategies and Requirements** *Centennial Ballroom II*	**Workshop VI:** **Current Trends and Future Directions of Clinical Trial Designs and Regulatory Science in US and China** *Haverford*	

3:30-3:45 AM
Grand Ballroom

Closing Remarks and Raffle Drawing

*** Please refer to Page 69 for the hotel layout.**

Agenda

June 23rd, 2017, Friday

Grand Ballroom

12:00 PM - 1:00 PM Check-in

1:00 PM - 1:10 PM Welcome Remarks

Bin Shi, PhD, President, SAPA-GP; Head of External R&D/Licensing, Amgen Asia R&D Center

1:10 PM - 1:30 PM Presidential Election Speeches

Zhenhua Wu, PhD, President-Elect, SAPA-GP; Associate Director, GlaxoSmithKline

Featured Presentation

1:30 PM - 2:00 PM

Grand Ballroom

1:30 PM - 2:00 PM Delivering Cell and Gene Therapy: One Big Pharma's Approach

Joseph Tarnowski, PhD, Senior Vice President, Cell and Gene Therapy Platforms, PTS, R&D, GlaxoSmithKline

Plenary Session I

2:15 PM - 3:45 PM

Grand Ballroom

Big Data and Artificial Intelligence: Emerging Paradigm to Accelerate Delivery of Transformational Therapies

Session Chairs:

Yuchen Bai, PhD, Associate Scientific Director, Johnson & Johnson

Han Dai, PhD, Scientific Leader, GSK Fellow, GlaxoSmithKline

2:15 PM - 2:45 PM The Role of Small and Big Data in Drug Discovery

Gunaretnam (Guna) Rajagopal, PhD, Global Head of Computational Sciences within Discovery Sciences, Janssen R&D

2:45 PM - 3:15 PM AI for Healthcare: Challenges and Opportunities.

Sean Zhou, PhD, Senior Director, Head of Computer Aided Detection and Diagnosis, Siemens Healthineers

3:15 PM - 3:45 PM Construction of Biomedical Big Data Platform in Shanghai Jiaotong University and the Children Hospital of Shanghai

Gang(Gilbert) Feng, PhD, Executive Director of the Big Data Platform in Shanghai Jiaotong University-Yale University Joint Center for Biostatistics and Senior Consultant in the National Center for Blood Disease Translational Medicine at Shanghai

3:45 PM - 4:15 PM Coffee Break

Workshop I

4:00 PM – 5:15 PM

Centennial Ballroom II

Position Yourself for the Future – Power Plan for Success

Co-organized with ASCEND,
the largest non-profit Pan-Asian organization for business professionals in North America

Session Chairs:
Haifeng Cui, PhD, GSK Fellow, Chief Scientist, GlaxoSmithKline
Hao Sun, MS, Senior Scientist, GlaxoSmithKline

4:00 PM - 4:25 PM Optimized Potential through Emotional Intelligence
Jen Groover, Human Potential & Business Expert, Author, International Speaker, Serial Entrepreneur, TV Personality, Inventor, Advisor, Advocate, Ascend

4:25 PM - 4:50 PM One Person, but Many Faces of Leadership: Flexing Your Style as a Leader
Sue Crimmin, PhD, Vice President, Sample Management Tech, GlaxoSmithKline

4:50 PM - 5:15 PM What's next?
Carolyn Buser-Doepner, PhD, Vice President, Head of Discovery Partnerships with Academia (DPAc), GlaxoSmithKline

Job Fair

2:00 PM - 5:00 PM

Centennial Ballroom I

Session Chairs:
Meizhen Feng, MS, Associate Principle Scientist, Merck & Co.
Yu Gao, MS, Research Associate, Teva Pharmaceuticals

VIP Session A

Frazer

2:30 PM – 4:30 PM

CEO Forum: Innovative Drug R&D in China

Session Chairs:
Sean Zhang, MD, FCP, Site Head, Board Member, CMO, Hengrui Therapeutics
Xue Liang, PhD, Microbiome Scientist, Merck & Co.

2:30 PM - 4:30 PM Panel Discussion
Mingjiu Chen, PhD, President and CEO, BioSynergics Inc.
Xu Chen, EMBA, President, ExCell Bio
Jim (Jingjun) Huang, PhD, CEO, Ascendia Pharmaceuticals
Larry Huang, PhD, President, Ark Pharm, Inc.
Feng (Frank) Li, PhD, President, Alliance Pharma
Simon Li, MD, PhD, Chief Medical Officer, Vice President of CSPC Pharma
Jay Mei, MD, PhD, Founder and CEO, Antegene Corporation
Weikang Tao, PhD, CEO of R&D Centers, Vice President, Jiangsu Hengrui Medicine Co., Ltd
Jingang Wang, EMBA, CEO, CoSci Med-Tech Co. Ltd
Philip Wang, VP, Hisun Pharmaceutical Company
Jingyi Wang, MD, PhD, President of Kelun Pharmaceutical Research Institute
Junzhi(John) Yao, PhD, co-founder and CEO, TC Scientific
Dan Zhang, MD, MPH, MA, CEO, Fountain Medical Development Ltd
Ming-Qiang Zhang, PhD, Vice President of R&D, Head of Amgen Asia R&D Center
De-Min Zhu, PhD, President and CEO, Curelong Group

Topics:

- What's the impact of current Chinese regulatory landscape changes on domestic and multinational pharmaceutical companies?
- Drug R&D in China:
  - The transformation from "Me-Too" to "First-in-Class" model
  - How will globalization impact the pharmaceutical industry in China?
  - Innovative drug discovery: what to expect in the next 10 years?
- Working for Chinese vs. multinational companies: opportunity, challenges, and cultural differences

VIP Session B

2:15 PM - 5:00 PM

Centennial Ballroom III

US-China Public Private Partnership (PPP): Biopharma Development Zones, Technology Transfer and Government Affairs

Session Chairs:
James Fendrick, BS, President and CEO, Rockland Immunochemicals, Inc.
David Cragin, PhD, Associate Director, Merck & Co.

2:15 PM - 2:45 PM The City of Philadelphia's China Initiatives and Our New Developments
Lauren Swartz, BA, Senior Director, International Business Investment, Department of Commerce, City of Philadelphia

2:45 PM - 3:15 PM Development of SOTIO Immunotherapy: A Czech-China Story
Vladimír Hrůša, MBA, CEO of Sotio Medical Research Co.

3:15 PM - 3:45 PM Partnering with the National Cancer Institute: An American Success Story
James Fendrick, BS, President and CEO, Rockland Immunochemicals, Inc.

3:45 PM - 4:15 PM Coffee Break

4:15 PM - 5:00 PM Panel Discussion
John Xu, MD, MBA, MS, Senior Vice President of Strategic Alliance, AbPro
Jim (Jingjun) Huang, PhD, CEO, Ascendia Pharmaceuticals
Lauren Swartz, BA, Senior Director, International Business Investment, Department of Commerce, City of Philadelphia
Vladimír Hrůša, MBA, CEO of Sotio Medical Research Co.

VIP Session C

2:15 PM - 5:00 PM

Harverford

US-China CRO Landscape: Building Success with Strategic Alliances

Featuring Participants from US and China CROs and Industry Executives

Session Chairs:
Li Cui, PhD, Investigator, GlaxoSmithKline
Weifeng Tang, MD, PhD, Director, AstraZeneca Pharmaceuticals

2:15 PM - 2:40 PM Connecting Science to Patients: Immuno-Oncology and Translational Oncology Platforms
Michelle Mack, MS, Director of Scientific Engagement, Crown Bioscience

2:40 PM - 3:05 PM CRO Landscape
Henry Lu, PhD, Vice President and Head of Biology, WuXi AppTec

3:05 PM - 3:30 PM Clinical Development Outsourcing
Karen Chu, Pharma D, Corporate Vice President, Clinical Research Services, Parexel

3:30 PM – 3:55 PM Animal Models in Drug Discovery on Immunotherapy
Jun Wang, PhD, Vice President of Biology, Shanghai Medicilon, Inc.

3:55 PM - 4:25 PM Coffee Break

4:25 PM - 5:00 PM Panel Discussion
Russell Dahl, PhD, Vice President, Global Business Development of Sundia
Mingjiu Chen, PhD, President and CEO, BioSynergics Inc.
Michelle Mack, MS, Director of Scientific Engagement, Crown Bioscience
Henry Lu, PhD, Vice President and Head of Biology, WuXi AppTec
Karen Chu, Pharma D, Corporate Vice President, Clinical Research Services, Parexel
Jun Wang, PhD, Vice President of Biology, Shanghai Medicilon, Inc.

Networking

5:00 PM – 6:00 PM

Gala Dinner (Invitation Only)

6:00 PM – 9:30 PM
Grand Ballroom

新乡市平原示范区
Pingyuan Demonstration Zone of Xinxiang

Gala Host:
Jing Yang, PhD, Senior Principal Scientist, Bristol-Myers Squibb Company
Fang Shen, PhD, Principal Scientist, Janssen R&D

6:00 PM – 6:05 PM Special Remarks
Jijun Xing, PhD, Science and Technology Counselor, Chinese Consulate-General in New York

6:05 PM – 6:35 PM Guest Presentation
Dengxi Wang, MS, Deputy Secretary, CPC Xinxiang Municipal Committee and Mayor, Xinxiang Municipal People's Government

6:35 PM – 6:50 PM Year-end Remarks
Bin Shi, PhD, President, SAPA-GP; Head of External R&D/Licensing, Amgen Asia R&D Center

6:50 PM – 6:55 PM SAPA-GP 2017-2018 Plan and Presidential Election Result
Zhenhua Wu, PhD, President-Elect, SAPA-GP; Associate Director, GlaxoSmithKline

6:55 PM – 9:30 PM Dinner and Networking

Agenda (con.)

June 24th, 2017, Saturday

7:30 AM - 8:30 AM Check-in and Continental Breakfast
8:30 AM - 8:35 AM Welcome Remarks
Zhenhua Wu, PhD, President-Elect, SAPA-GP; Associate Director, GlaxoSmithKline

Featured Presentation

8:35 AM - 9:25 AM
Grand Ballroom

8:35 AM - 9:00 AM Kelun- Scientific Truth— Seeking, Ethics for Good
Jingyi Wang, MD, PhD, President of Kelun Pharmaceutical Research Institute

9:00 AM – 9:25 AM Situation and Present Policies of China's Pharmaceutical Industry
Mingde Yu, Honorary President and Chair of Expert Committee, China Pharmaceutical Enterprise Association

Plenary Session II

9:30 AM - 10:30 AM
Grand Ballroom
Innovative Medicines: Transforming Patient Care

Session Chairs:
Yongchao Su, PhD, Associate Principal Scientist, Merck & Co.
Hanghang Zhang, PhD Candidate, Fels Institute of Cancer Research, Temple University

9:30 AM - 10:00 AM Together to Create a World Without Lung Cancer
Li Mao, MD, Vice President and Head of the Johnson & Johnson China Lung Cancer Center

10:00 AM - 10:30 AM Engineering the Environment of the Gut to Treat Inflammatory Bowel Disease
Gary D. Wu, MD, Ferdinand G. Weisbrod Professor in Gastroenterology, University of Pennsylvania, School of Medicine

10:30 AM - 10:45 AM Coffee Break

Workshop II

10:45 AM - 12:15 PM
Centennial Ballroom III
Regulatory and Market Access

Regulatory Pathways for Bringing Innovative Products to Markets: Addressing the Needs of Patients and Payers

Session Chairs:
Jim Wang, PhD, MBA, Head of Regulatory Affairs Strategy, Spark Therapeutics, Inc.
Yufeng Li, PhD, Clinical Scientist, GlaxoSmithKline

10:45 AM - 11:15 AM Orphan Product Development from First-in-Human Study to Regulatory Approval
Jim Wang, PhD, MBA, Head of Regulatory Affairs Strategy, Spark Therapeutics, Inc.

11:15 AM - 11:45 AM Development of Target Product Profile and Product Labeling
Paul Savidge, JD, MBA, Senior Regulatory Counsel, Spark Therapeutics, Inc.

11:45 AM - 12:15 PM Health Outcome Analysis for Payer Endorsement
Kim Gilchrist, MD, MBA, Senior Director, Value Evidence & Outcomes, GlaxoSmithKline

Workshop III

10:45 AM - 12:15 PM
Centennial Ballroom II
Perspectives of Biopharma R&D in China

Session chairs:
John Xu, MD, MBA, MS, Senior Vice President of Strategic Alliance, Abpro
Mengjie Si, PhD Candidate, School of Pharmacy, Temple University

10:45 AM - 11:15 AM Pharmaceutic R&D in China: Opportunities and Challenges and Keys to Managing a MNC R&D Center in China
Ming-Qiang Zhang, PhD, Vice President of R&D, Head of Amgen Asia R&D Center

11:15 AM - 11:45 PM Innovative Drug R& D in China: HengRui's Experience and Perspectives
Weikang Tao, PhD, CEO of R&D Centers, Vice President, Jiangsu Hengrui Medicine Co., Ltd.

VIP Session D

9:30 AM - 12:00 PM
Haverford
Pharma/Healthcare Global Deal Dynamics Forum
Mergers and Acquisitions (M&A), Investment, and Business Development (BD)

Session Chairs:
Patrick Deng, MBA, Finance Director, Johnson & Johnson

Michael Tang, JD, Tax Associate, EY

9:30 AM - 10:00 AM M&A and BD to Drive Exceptional Growth in Pharma/Generic Business
Jie Liu, MBA, Managing Director, New York Office, Torreya Partners

10:00 AM - 10:30 AM Deal Structure and Legal Considerations in Cross-border M&A and Investment Deals
Liang Xu, LLM, Partner, Hogan Lovells International

10:30 AM - 11:00 AM China Inbound M&A: Valuation Drivers & Tax Impacts
Min Fei, MS, Partner and China Tax Desk Leader, International Tax Services, EY
Yudan Zhang, CPA, MSA, Senior Manager, Transaction Advisory Services, EY

11:00 AM - 11:30 AM Coffee Break

11:30 AM - 12:00 PM The Cultural and Legal Challenges for Chinese Companies Doing Acquisition or Investment Deals in the US
Zhiping Liu, JD, Partner, Liu, Zheng, Chen & Hoffman LLP
Yong Chen, JD, PhD, Partner, Liu, Zheng, Chen & Hoffman LLP

VIP Session E

9:30 AM – 12:00 PM, 1:30 PM - 3:30 PM
Centennial Ballroom I
SAPA-Hopkins Venture Forum

SAPA-Hopkins Venture Forum is a joint event proudly organized by Sino-American Pharmaceutical Professional Association-Great Philadelphia(SAPA-GP) and The Hopkins Club for Innovation and Entrepreneurship (The Hopkins Club). The forum brings together pharma and biotech leaders, emerging fast-growing companies, technology innovators, and members of the investment community with a focus on biohealth innovation and assets.

9:30 AM – 12:00 PM
Session Chair:
Ying(Charles) Wang, PhD**,** Scientific Director, GlaxoSmithKline
Zhen Lu, PhD, Application Scientist, Flarebio

1:30 PM - 3:30 PM
Session Chair:
Han Dai, PhD, Scientific Leader, GSK Fellow, GlaxoSmithKline
Jiayi Zhang, PhD, Scientist, Paragon Bioservices

Selected Portfolio Companies:
Harborgen Biotechnology
Renman Therapeutics LLC
Beta Biosciences, Inc.

Center for Applied System Biology, Inc.
TeraImmune LLC
B&H Biotechnologies LLC
DaVinci Healthx, Inc.
Anson Diagnostics, Inc
Cosmos Insight LLC
LINKSciences

Lunch

11:45 AM - 12:45 PM

CSPC 石药集团

Lunch Session

12:15 PM - 1:15 PM

Aiming for Success: Biotechnology Entrepreneurship Boot Camp — **Ardmore**

Session chair: ***Xianhua Li***, PhD Candidate, Villanova University, Department of Chemical Engineering
Speaker*: Dennis Gross*, PhD, CEO and Treasurer, Pennsylvania Drug Discovery Institute

Six Key Successful Retirement Strategies — **Paoli**

Session chair: ***Yutai Li***, PhD, Principal Scientist, Merck & Co.
Speaker*: Carolyn Choh*, MBA, Investment Adviser Representative with Financial Independence Planning, LLC.
Harry Keller, CFP®, ChFC, CLU, MBA, CEO and Founder of Financial Independence Planning, LLC

Executive Development Programs: A Gateway to Leadership Excellence — **Frazer**

Session chair: ***Hui Wang***, PhD, Application Scientist, LINKSciences

Speaker: *Gaëlle Beltran-Grémaud*, MBA, Senior Director, Aresty Institute of Executive Education, Wharton School, University of Pennsylvania
Michael Malefakis, MIA, Associate Vice Dean, Aresty Institute of Executive Education, Wharton School, University of Pennsylvania

Latest Developments in PIV Litigation and New Opportunities for Obtaining Generic Exclusivity — **Devon**

Session Chair: ***Dan Tian,*** PhD, University of the Sciences
Speaker*: Stephen Yang*, JD, Senior Associate, Alston & Bird LLP
Thomas J. Parker, JD, Partner, Alston & Bird LLP

Workshop IV

1:30 PM - 3:30 PM

Centennial Ballroom III

Navigating through the Changing Regulatory Environment

CMC, Regulatory, Legal and Data Integrity Aspects of Bioequivalence studies

Session Chairs:

Lu Wang, PhD, Senior Scientist, Teva Pharmaceuticals

Chengwei Fang, PhD, Principal Investigator, DuPont Crop Protection

1:30 PM - 2:00 PM BA and BE Overview

Bangqian Xu, PhD, Chief Operating Officer, Oryza Pharmaceuticals Inc.

2:00 PM - 2:30 PM BE Study: Its Applications in Pharmaceutical Industry

Daniel Du, MD, PhD, Vice President of Clinical Services at Frontage Clinical Services, Inc.

2:30 PM - 3:00 PM Coffee Break

3:00 PM - 3:30 PM ANDA Filing, Hatch Waxman Litigation, and Post Grant Patent Challenge

Jason Luo, JD, PhD, Patent Attorney, Duane Morris LLP

Workshop V

1:30 PM - 3:30 PM

Centennial Ballroom II

Biosimilar Development: Strategies and Requirements

Session Chairs:

Yu Gao, MS, Research Associate, Teva pharmaceuticals

Yang Liu, PhD, Investigator, GlaxoSmithKline

1:30 PM - 2:00 PM Demonstration of Biosimilarity

Patrick Liu, MD, PhD, Vice President of Biologics R&D and Head of Global Bioassays and Technology, Teva Pharmaceuticals

2:00 PM - 2:30 PM Biosimilar Exclusivity and Interchangeability: A Legal Primer

Xin Tao, JD, Senior Associate, Hogan Lovells US LLP

2:30 PM - 3:00 PM Coffee Break

3:00 PM - 3:30 PM Biosimilar Development in the US from Quality and Regulatory Perspective

Audrey Jia**,** PhD, Independent Consultant

Workshop VI

1:30 PM - 3:30 PM

Harverford

Current Trends and Future Directions of Clinical Trial Designs and Regulatory Science In US and China

Session Chairs:
Shuang (Steve)Wu, PhD, MS Candidate in Biostatistics, Columbia University
Hao Wu, PhD, Technical Specialist, Howson & Howson, LLP

1:30 PM - 2:00 PM ICH 17 and Global Drug Development
William(Bill) Wang, PhD, Executive Director, Clinical Safety Statistics, Biostatistics and Research Decision Sciences(BARDS), Merck Research Laboratories

2:00 PM - 2:30 PM Safety Issues in Clinical Trials
Huabin Sun, MD, Medical Safety Officer/Director, Global Medical Safety, Janssen R&D

2:30 PM - 3:00 PM Coffee Break

3:00 PM - 3:30 PM In parallel Development of Clinical Programs in US and China
***Simon Li*,** MD, PhD, Chief Medical Officer, Vice President of CSPC Pharma

3:30 PM - 3:35 PM Closing Remarks **Grand Ballroom**
Zhenhua Wu, PhD, President-Elect, SAPA-GP; Associate Director, GlaxoSmithKline

3:35 PM – 3:45 PM Raffle Drawing **Grand Ballroom**
Hui Wang, PhD, Application Scientist, LINKSciences

Biographies

Listed in Alphabetical Order

Gaëlle Beltran-Grémaud, MBA, Senior Director, Aresty Institute of Executive Education Wharton School of the University of Pennsylvania

Gaëlle Beltran-Grémaud is a Senior Director at the Aresty Institute of Executive Education Wharton School of the University of Pennsylvania. She is responsible for developing and managing a portfolio of customized executive education programs targeted towards senior executives in hospital systems, medical device, bioscience and pharmaceutical companies. Through a customized consulting methodology, Gaëlle and her team work with health care clients and Wharton faculty to develop curricula, select faculty, and create learning experiences that will produce results based on client derived goals.

Some of the clients Gaëlle and her team have partnered with include, among others: the American Academy of Pediatric Dentistry (AAPD), the Anesthesia Business Group (ABG), the American Association of Colleges of Nursing (AACN), the UPenn School of Nursing, MedStar Health, UnitedHealthGroup, Roche/Genentech, Merck, GSK, BMS, Johnson & Johnson, Novartis, and Novo-Nordisk.

Prior to joining Wharton Executive Education Gaëlle worked for pharmaceutical companies both in France and the US. In her role as Manager Corporate Development for Ethypharm USA Corp, Gaëlle helped the CEO secure commercial partnerships for generic and brand products in the US, Canada, and South America. As a CRM Project Manager for Eli Lilly in France, Gaëlle managed a large CRM project aimed at implementing a customer-centric business model in the French affiliate, starting around the launch of a new innovative drug but with a view to implementing this business model across the organization.

Gaëlle also worked as a consultant in telecommunications and e-business for Arthur D. Little in San Francisco and later on for *e-conseil*, a small consulting firm she co-founded in Paris, France. Gaëlle's broad international experiences in both management consulting and in the pharmaceutical industry makes her fully aware of the challenges facing health care and pharmaceutical companies in the ever changing health care eco-system. Gaëlle graduated from HEC Business School in France where she is originally from and later received her MBA from INSEAD. Gaëlle is also a food blogger and very keen on trying out new international food at home or when she travels. She lives in Philadelphia with her husband and their two children.

Carolyn Buser-Doepner, PhD, Vice President, Head of Discovery Partnerships with Academia, GlaxoSmithKline

Carolyn A. Buser is Vice President of Discovery Partnerships with Academia (DPAc) at GlaxoSmithKline. She received her BA/BA in chemistry and German from Bryn Mawr College. She spent one year as a Fulbright Scholar at the Technical University of Braunschweig in Germany, and obtained her PhD in Biophysical Chemistry at Yale University in 1992. She was a Damon Runyon – Walter Winchell postdoctoral fellow at the State University of NY at Stony Brook and subsequently served as Research Assistant Professor. In 1996, Carolyn joined the Oncology group at Merck Research Labs, holding positions as preclinical team leader for several drug discovery programs, director of Oncology Health Care Solutions, and finally senior director of External Scientific Affairs in Oncology. In March 2011, Carolyn joined GlaxoSmithKline (GSK), where she now leads a team of drug development scientists who identify and progress novel targets in partnership with biology and disease experts in academia. Within GSK, she co-chairs the GSK Fellows Program, is a member of the Technology Investment Board, and a rotating member of the Discovery Investment Board. Carolyn is a member of AACR and AAAS and is bilingual in German.

Mingjiu Chen, PhD, President and CEO, Biosynergics, Inc.

Mingjiu Chen, PhD, founder and CEO of Biosynergics Inc., which is focusing on the innovative therapeutic antibody discovery and development – by using their proprietary H3 antibody technology platform and synergistic antibody development platform. Before starting up his own business, Dr. Chen served as Senior Director of Operations at Strategic Diagnostics (SDIX), leading their Monoclonal Antibody Operations, accomplished over 100 commercial antibody development programs for industrial and/or academic clients. From 2007 to 2010 Dr. Chen served as Senior Scientist of Abbott Laboratories (now AbbVie), advancing hybridoma technology for therapeutic antibody discovery and early development. Before joining Abbott, Dr. Chen held Principle Research Associate of Lexicon Pharmaceuticals from 2001 to 2004, a visiting scholar at Kumamoto University School of Medicine from 1995 to 1997, and an Assistant Investigator of SinoPharm from 1990 to 1995. Dr. Chen has a PhD in Molecular Medicine from the University of Texas Health Science Center at San Antonio, an MS in Animal Genetics from Central China Agricultural University and a BS in Animal Husbandry from Inner Mongolia Agricultural University, China.

Xu Chen, EMBA, President, ExCell Bio

Xu Chen is the founder and president of ExCell Bio Company. He is also the initiator of the renowned agency company "Genetimes" engaging in biological reagents and devices. With over 24 years of experience in biological field, he successfully introduced the famous international companies Sigma, Corning, GE Hyclone and such like into Chinese market and became an experienced professional in Chinese Bio-reagent trade. Chen, Xu had been taking on the manager of the

international department, the sales manager of the Beijing branch and the vice general manager of the Shanghai branch in SABC, which is the first biotechnology corporation in China. Chen, Xu graduated from Institution of Biology in Nankai University and obtained EMBA degree. Socially he is the council member of China Entrepreneur Association, the Senior member of the international ethnic Chinese biomedical organization Bayhelix, the executive director of Shanghai Management Science Society, the standing member of Shanghai Federation of Industry and Commerce, the leading talent of scientific and technological innovation and enterprising in Taicang, Jiangsu. He has been elected the representative of the ninth Shanghai Association for Science & Technology and so on.

Yong Chen, JD, PhD, partner of Liu, Zheng, Chen & Hoffman LLP

Dr. Yong Chen is a partner of Liu, Zheng, Chen & Hoffman LLP, a boutique business law firm started by experienced attorneys having Chinese background with practices covering areas of general corporate, mergers & acquisitions, financing, capital markets, technology transfer, intellectual property, and real estates. Dr. Chen's practices focus on intellectual property, including patent and trademark application preparation and prosecution, patent portfolio development and management, licensing, transaction, and litigation.

Prior to co-founding Liu, Zheng, Chen & Hoffman LLP, Dr. Chen worked at Baker Botts LLP, Stroock & Stroock & Lavan LLP, and Ascenda Law Group PC as a patent attorney for more than 8 years, during which time he counseled a range of clients including petrochemical, chemical engineering, pharmaceutical, medical devices companies, universities and research institutions in their patent and trademark portfolio management, application preparation and filing, prosecution, patent invalidity investigation, patent infringement investigation, freedom-to-operate studies, due diligence, technology transfer and licensing.

Dr. Chen earned his JD from New York University, his PhD in Chemistry from the Graduate Center of the City University of New York, his MS and BS in Polymer Science and Engineering (Materials Sciences and Engineering College) from Beijing University of Chemical Technology. Dr. Chen is admitted in New York and the U.S. Patent and Trademark Office.

Carolyn Choh, MBA, Investment Adviser Representative with Financial Independence Planning, LLC.

After graduation, Carolyn joined the pharmaceutical industry where she held increasing responsibility in sales and marketing. Carolyn was a global product director at Wyeth and later Vice President at Saatchi & Saatchi. She transitioned her experience into teaching pharmaceutical marketing and was a professor at Saint Joseph's University for over 10 years prior to joining the FIP team. Carolyn is committed to the importance of life-long education. Carolyn has conducted financial education seminars focused on the topics of financial planning around life events: "What to do When a Loved one or Spouse Passes" and "6 Steps when Faced with a Corporate or Life Transition".

She is also planning a series of workshops for women, "Fabulous after Fifty – a Focus on Physical and Financial Health".

Carolyn is a registered investment adviser representative with Voya Financial Advisors and has the series 7 and 66 securities registrations. She also has Life, Health and Disability insurance licenses with the State of PA. Carolyn has her BA in Biochemistry/Asian Studies and MBA from Cornell University.

Karen Chu, PharmD, Corporate Vice President, Clinical Research Services, Parexel

In her role as Corporate Vice President for Clinical Research Services, Karen has the responsibility as the Global Head for Clinical Operations. Karen's responsibilities include the oversight of site management and functional lead role within Clinical.

Prior to PAREXEL's acquisition of APEX International Clinical Research Co., Ltd., Ms. Chu joined APEX in 2005 as the Executive Director for all clinical operations including Project Management, Clinical Operations, Data Operations & Statistical Analysis, Medical and Regulatory Affairs at APEX. In 2013, Karen transitioned to a global responsibility as the Worldwide Head for Project Support and Planning and Records Management while supporting the Asia Business.

In addition, she has extensive experiences with clinical trials both globally and in the APAC region, as well as a unique understanding of the diverse regulatory landscape in the Asia-Pacific region.

Ms. Chu holds both Bachelor of Science and Doctor of Pharmacy degrees from Rutgers, The State University of New Jersey, College of Pharmacy.

David Cragin, PhD, Associate Director of Chemical Notification and Registration for Merck & Co.

Dr. Dave Cragin is the Associate Director of Chemical Notification and Registration for Merck & Co. Since 2009, he's been an active member of both SAPA (HQ) and SAPA GP including serving in roles such as Communication & Outreach, Scientific Programs, and as Language and Culture Consultant. He's been a speaker and host for meetings and career sessions for SAPA (HQ), SAPA GP, and SAPA CT. Dr. Cragin is passionate about SAPA. He knows of no other professional society that so effectively blends the technical, business, and career aspects of its industry. Also, helping and mentoring SAPA members is something he enjoys and many in-turn, have helped him with his Chinese and other career issues. He speaks Chinese and is knowledgeable in many languages. Building and enhancing ties with China is important to him. Since 2008, he has taught as a Professor of the International Program in Pharmaceutical Engineering Management of *Peking University*, Beijing, China. This year, he will also teach for the Environmental Sciences program at Beijing Normal University. Additionally, he's an Adjunct Professor of Health Policy and Public Health for the *University of the*

*Science*s, Philadelphia. Dr. Cragin is a Trustee of the *Toxicology Education Foundation* and Past-President of the *Mid-Atlantic Society of Toxicology*, the largest chapter of the *Society of Toxicology*. He received his Ph.D. in Pharmacology and Toxicology from *University of California, Davis,* his B.S. in Zoology from the *University of Rhode Island*, and is a Diplomate of the *American Board of Toxicology*.

Sue Crimmin, PhD, Vice President, Sample Management Tech, GlaxoSmithKline

Dr. Sue Crimmin is VP and global head of Discovery Supply at GSK. This worldwide organization is accountable for the acquisition, development and management of GSK biological (including Human Biological Samples) & small molecule collections and the maintenance & distribution of preclinical, clinical and post clinical trial samples and collections including compliance and QA. She is a recognized industry expert in sample management and automation and is currently a member of the Americas Council for SLAS (Society of Laboratory Automation and Sciences). She was awarded a fellowship of the Society in 2017 in recognition of her work as a board member, short course chair and member of the editorial board and instructor. Sue has worked in areas of Automation, Sample Management; high throughput screening (HTS), target development and IT during her career which has spanned 3 countries and major sites within the GSK operation. She led the successful development and implementation of sample handling automation systems for high throughput screening at GSK. She has held many global roles including Quality Assurance and New Technologies and has recently led efforts to redesign sample logistics across GSK platforms. Sue holds a PhD in Microbial Biochemistry and is a trained Lean Sigma facilitator. Sue is passionate about people development and leads group across GSK in the Delaware Valley which facilitates development training.

Russell Dahl, PhD, Vice President, Global Business Development of Sundia MediTech

Dr. Russell Dahl is Vice President, Global Business Development of Sundia MediTech Company. Sundia is a leading Chinese CRO offering fully integrated drug discovery services for Pharmaceutical and Biotech companies, working with a majority of the top US companies. Previously, Russell led all small molecule drug discovery efforts for Celladon Corporation, a clinical-stage biotechnology company. Dr. Dahl also held multiple leadership roles in Big Pharma, including stints at DuPont Pharmaceuticals, Bristol-Myers Squibb, and Vertex Pharmaceuticals. During his tenure, he contributed to the discovery of multiple clinical drug candidates for major diseases. A prolific multidisciplinary and entrepreneurial scientist, he has also founded or been involved in the founding of multiple startup biotech companies developing breakthrough medicines. Dr. Dahl has also held tenure track academic posts in Medicinal Chemistry and Drug discovery and is a highly-regarded lecturer. He has co-authored over 80 peer-reviewed manuscripts and is an inventor on over 20 patents in therapeutics and chemistry.



Han Dai, PhD, Scientific Leader, GSK Fellow, GlaxoSmithKline

Dr. Han Dai is currently a GSK Fellow in Alternative Discovery & Development TAU at GSK and also a GSK Visiting Professor at High Magnetic Field Laboratory, Chinese Academy of Sciences. He has been working in the pharmaceutical industries for ~9 years, starting with responsibilities in protein chemistry, enzymology, biophysics & structural biology and expanding quickly into preclinical drug discovery program management and leadership, covering also cell biology, DMPK, and pharmacology aspects of programs. He has published more than 40 papers, book chapter, abstracts and patents in reputed journals (including Nature Communications, Nature Structural and Molecular Biology, Science, Cell), and conferences, serving as the first and corresponding author, an invited reviewer for more than 10 peer reviewed journals (including PNAS, MBC), an editorial board member for Journal of Vaccine & Immunotechnology, and an invited speaker at several conferences. He is also actively involved in community services, including GSK Alternative Discovery & Development Communications and Engagement, GSK R&D Data Science Matrix Group, F1000 Drug Discovery & Design Section as a Full Faculty Member. Han is a lifetime SAPA member, and currently serves as the Vice President of Business Development of SAPA-GP and the Executive Council member of SAPA. Han completed his Bachelor of Science in Department for Intensive Instructions at Nanjing University in Nanjing, China, his PhD at UT Southwestern Medical Center at Dallas as a Frank and Sara McKnight fellow, his postdoctoral training in Harvard Medical School as a Helen Hay Whitney fellow.

Daniel Du, MD, PhD, Vice President of Clinical Services, Frontage Clinical Services, Inc.

Daniel Du, MD, PhD is a senior clinical researcher with more than 20 years of experience in pharmaceutical industry. Currently, he is the VP of Clinical Services at Frontage Clinical Services, Inc. He has worked in multiple therapeutical areas including Nephrology, Dermatology, CNS, Smoking Cessation, Allergic Rhinitis, and OTC drugs with experience spanned from Phase 1 to 4. He was the clinical development lead for several Phase 3 programs and Rx-to-OTC switch when he worked in Pfizer, GSK Consumer Healthcare, and Akebia. Over the years, he filed 15 patents and published more than 20 manuscripts in peer-reviewed journals.

Min Fei, MS, Partner and China Tax Desk Leader, International Tax Services, EY

Min is a member of Ernst & Young LLP, the US EY member firm, where she leads the China Tax Desk — Global Tax Network. Previous to her New York assignment, she was an International Tax Services partner at Ernst & Young (China) Advisory Limited, Shanghai, providing client advice on tax and regulatory issues arising from operations in China and the Asia-Pacific region. Min also had more than seven years of US international tax practice experience in Chicago at the beginning of her career, which makes her advice to the U.S. clients more relevant.

费敏, 合伙人, 中国税务部, 美国安永, Ernst & Young LLP

费敏是美国安永事务所中国税务部的领导合伙人。 在此之前， 费敏负责中国安永华中区的国际税务部业务。

费敏的事业起始于美国安永事务所的芝加哥团队。 在芝加哥的七年多， 她做为一名国际税务咨询师协助美国企业的境外运营和投资。 鉴于她的出色工作表现， 费敏于 2004 年被派遣到中国以协助客户在中国和亚太区的运营， 并开始发展针对中国企业需求的服务项目。

费敏自 2006 年起开始协助中国企业的境外投资。 这些年来， 她经常受邀参与中国国家税务总局针对中国企业走出去的税务政策讨论。 费敏以她的美国国际税背景， 中国税务专业技术， 和各种跨国项目的实务经验协助于中国客户的境外投资， 相关国家包括但不限于加拿大， 美国， 墨西哥， 巴西， 德国， 英国， 迪拜， 以色列， 南非澳大利亚， 和印度。 她曾致力服务过的客户包括复星集团， 上海中福地产， 上汽集团， 西电集团武钢， 金风科技， 无锡尚德， 阿特斯太阳能， 和徐工集团。 费敏具有成功服务中国国企和民企国际化进程中所需的扎实理论技术和实践经验。

费敏成长于中国浙江省杭州市， 本科毕业后赴美深造。 她毕业于麻省州立大学的财务会计研究生院， 并执有伊立诺伊州的注册会计师证书。

James Fendrick, BS, President and CEO, Rockland Immunochemicals, Inc.

Mr. Fendrick is President and CEO of Rockland Immunochemicals, Inc. Rockland is a global biotechnology company that is renowned for its development of assays, antibodies and antibody based tools. Rockland conceives and produces monoclonal and polyclonal antibodies against targets involved in cancer and other molecular signaling pathways which are incorporated into immunoassays for detection of biomarkers for various diseases. Partnering with leading government, academic and biopharma institutions and organizations throughout North America, Europe and Asia is a cornerstone of Rockland's success. For example, in collaboration with the National Cancer Institute's Center for Cancer Research and the MD Anderson Cancer Center, Rockland recently released a suite of research reagents used to assess patient suitability for certain cancer therapies. Rockland's proprietary technology and expertise spans a broad spectrum – from Lyme disease assays to VHH single-domain antibody platforms and beyond. Rockland is located in Limerick, Pennsylvania. Jim is a graduate of Gettysburg College.

Gang(Gilbert) Feng, PhD, Executive Director of the Big Data Platform in Shanghai Jiaotong University-Yale University Joint Center for Biostatistics and Senior Consultant in the National Center for Blood Disease Translational Medicine at Shanghai

Dr. Gang (Gilbert) Feng is the executive director of the Biomedical Big Data Platform in the National Center for Blood Disease Translational Medicine at

Shanghai and the Center of Biotechnology Informatics in the National Center for Molecular Translational Medicine at Xi'an. He is also the adjunct faculty member for Shanghai Jiaotong University-Yale Joint Center for Biostatistics, Northwestern University, Prevention Medicine, Health and BioMedicial Informatics(HBMI) Division and the 4th Military Medicine University. He got his BS in Biological Science and Biotechnology at Tsinghua University, MS in Biophysics and Computational Biology at University of Illinois at Urbana-Champaign, and PhD in Bioinformatics at University of Illinois at Chicago. Then he joined Northwestern University Feinberg School of Medicine as the senior biomedical informatics scientist and executive director of the Biomedical Informatics Research Collaboratory (BIRC), a part of the Center of Cancer and Nanotechnology Excellence (CCNE, supported by NCI), Robert H Lurie Comprehensive Cancer Center(supported by NCI), the Clinical and Translational Science Institute (NUCATs, supported by NIH) as well as a research track faculty member in the Department of Preventive Medicine. He had conducted and collaborated more than 100 high-dimensional clinical and research data analytical projects as well as published more than 20 peer review papers on high rank journals such as Nature Communications, PNAS, Bioinformatics, etc. He also developed two packages in Bioconductor, which is the largest international bioinformatics developing community. Both of them had been downloaded thousands of times. As the co-PI and key personal, he contributed a lot to a couple of projects funded by NIH, NCI and NSF. Due to his outstanding work, he was honored with caBIG Delivering Results Award by NCI. After he left from Northwestern University, he joined Appistry, a St. Louis based commercial cloud company focusing on biomedical applications and served NIH, FedEx and Lockheed-Martin, etc. He led a team to develop and integrate biomedical software on the commercial cloud computing platform.



Kim Gilchrist, MD, MBA, Senior Director, Value Evidence & Outcomes, GlaxoSmithKline

Dr. Gilchrist joined GlaxoSmithKline supporting Infectious Disease area, Value Evidence and Outcomes in 2011. She is a Health Outcomes Research leader as well as Board Certified Internal Medicine Practitioner, and Microbiologist with 20 years' experience in clinical teaching and pharmaceutical drug development. Her most recent infectious disease drug development focused on antibacterial, antiviral, and two HIV antiretroviral products (Dolutegravir, Efavirenz). Prior to joining GSK, she led the US Health Outcomes group at AstraZeneca overseeing a full portfolio of products within respiratory, cardiovascular, oncology and infectious disease. Her early career focused on all facets of clinical development, particularly phase IIIB and IV, Medical Affairs and Professional information, Promotion and Medical review of advertising while at AstraZeneca and Dupont Pharmacueticals. During her free time, she enjoys outdoor activities, sports, and dance in addition to time with her family.

Jen Groover, Human Potential & Business Expert, Author, Int'l Speaker, Serial Entrepreneur, TV Personality, Inventor, Advisor, Advocate, Ascend

Jen Groover has been tagged by SUCCESS MAGAZINE as a "One-Woman Brand," a "Creativity and Innovation Guru" and a leading "Serial Entrepreneur" by Entrepreneur Magazine and ranked #8 by SAP in the Top 51 Influencers of Human Potential. Her name has become synonymous with innovation, entrepreneurship and transformation. She was recently nominated as a UN delegate to the first ever Global Accelerator for the Global Entrepreneurs Council. She also made history at the NYSE, as a member of the first all-female group to ring the opening bell, made Forbes' list of "50 Founders You Need to Follow on Twitter" and was nominated "TV Personality of The Year Award" in 2013 by Savor the Success.

Jen's energy and multi-faceted, diverse wisdom make her a highly sought after international speaker for Fortune 500 companies to top Universities, Non-Profits, Chamber of Commerces, Business Conferences, and more, on topics ranging from business to leadership, empowerment to emotional intelligence to healthy living, and enhancing productivity. Her influence and leadership has aligned her with amazing brands, such as Avon, Independence Blue Cross, Verizon, USANA Health Sciences and SkyMall, for which Jen has had various roles as a spokeswoman and consultant for brand development and leadership training. She regularly advises professional athletes, Olympic athletes, entrepreneurs and CEO's on strategies to optimize their potential as well as expand their brands.

Dennis M. Gross, PhD, CEO & Treasurer of Pennsylvania Drug Discovery Institute

Dennis M Gross, PhD, is the CEO, Treasurer and Professor of Pharmacology for the Pennsylvania Drug Discovery Institute and Professor of Experimental Therapeutics and Medicinal Chemistry at the Baruch S. Blumberg Institute of the Hepatitis B Foundation. He is also Faculty in the Jefferson College of Biomedical Sciences and the Sidney Kimmel Medical College of Thomas Jefferson University (TJU). He recently retired from full-time status at TJU where he was the Associate Dean for Program Development and Assessment and Director for the Professional Science Masters Programs. He was also Associate Professor of Pharmacology & Experimental Therapeutics in the Jefferson Medical College. Prior to this, he was at the Merck Research Labs for 29 years retiring in 2006 as Senior Director and Head of West Point Business Operations with overall responsibilities for capital planning and facilities in Pennsylvania, California and Massachusetts. He was also responsible for capital lab projects and operations oversight at Merck lab sites in Canada, Japan, Italy and the UK. In his career at Merck he held a number of positions ranging from bench scientist to head of computer resources, divisional data security administrator, manager of international strategic planning, M&A activities and liaison for basic research and clinical drug development in Japan.

During his tenure at Merck, he also served as Adjunct Professor of Global Logistics in the School of Business and Industry of Florida A&M University. He has worked with the Center for Strategic &

International Studies in Washington, DC on policy issues relating to biological weapons of mass destruction. He received his BA (1969) and MS (1970) from California State University Northridge and his PhD (1974) from UCLA pursuing a postdoctoral fellowship at Tulane University School of Medicine. He has also participated in executive education programs at Wharton, MIT and the Tufts School of Law and received FEMA NIMS and ICS certification. He is a member of the American Association for Pharmaceutical Scientists, American Chemical Society, American Heart Association, Global STEM Alliance, History of Science Society, International Society for Pharmaceutical Engineering, and Sigma Xi.

Vladimír Hrůša, MBA, CEO, SOTIO Medical Research Co.

Vladimír is a graduate of The University of Economics Prague, Czech Republic, where he studied mathematical method in economics. Later he obtained an MBA degree from De Paul University Chicago. Prior to joining SOTIO, he was a CFO and held other managerial positions in several multinational companies in the area of services, production and sales & distribution. He also held for nearly 5 years a managerial position in a consulting company with focus on M&A, restructuring and appraisal. His main area of operation was the CEE region. Vladimír joined SOTIO in 2013 as CFO of SOTIO China. In September 2016, he was appointed the CEO of SOTIO Medical Research Co., Ltd. in China.

Jim (Jingjun) Huang, PhD, CEO, Ascendia Pharmaceuticals

Dr. Huang founded Ascendia in 2012 after fifteen years of pharmaceutical R&D and management experience at Pfizer, Baxter, AstraZeneca, and most recently Roche. He has led the formulation development efforts for the successful transition of several oral and parenteral dosage forms from discovery through formulation, manufacturing, technical transfer and ultimately commercialization. Dr. Huang holds a PhD in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) where he worked with Joseph B. Schwartz. Dr. Huang's research interests are centered on improvement of solubility and dissolution, and controlled delivery of, poorly water soluble drugs through nano-emulsion, nanoparticles, and amorphous solid dispersion technologies. He has published numerous patents and papers and serves as reviewer for leading pharmaceutical journals.

Currently, he is a member of American Association of Pharmaceutical Scientists (AAPS) and American Chemical Society (ACS).

Larry Huang, PhD, President, Ark Pharm, Inc.

Larry Huang received his PhD in organic chemistry from Shanghai Institute of Organic Chemistry, CAS in 1993 and completed postdoctoral training in Medicinal Chemistry at University of Illinois at Chicago from 1994 to 1997. Dr. Huang co-found SynChem, a CRO company in 1997, served as CSO. In 2007, he founded Ark Pharm, a leading supplier of building blocks, scaffolds and advanced intermediates serving drug discovery research, covered about 225,000 SF space in Chicago and Shanghai, with over 300 employees.

Audrey Jia, PhD, Independent Consultant

Dr. Jia has 17 years of combined experience in biologic drug development and regulatory review. Currently Dr. Jia is an independent consultant for biological drug development especially monoclonal antibody relevant products.

During her time in US FDA from year 2009 to 2015, Dr. Jia was a full time CMC reviewer for IND/BLA review of biological products especially monoclonal antibodies including antibody fragments, fusion proteins, antibody drug conjugate, combination products, and radiolabeled antibodies. She performed numerous IND reviews, several BLAs (including post approval reviews), and several US and international cGMP pre- approval inspections (PAIs). She is specialized in both novel proteins/antibodies and biosimilar products.

Dr. Jia spent 10 years in the biopharmaceutical companies working on biological product including monoclonal antibody engineering, humanization, affinity maturation, expression, and purification.

Dr. Jia hold a Master degree in Bioscience Regulatory Affairs from Johns Hopkins University, and a PhD degree in Microbiology and Molecular Genetics from Emory University. Prior to that, Dr. Jia obtained her Bachelor degree of Medicine from Peking University.

Harry Keller, CFP®, ChFC, CLU, MBA, CEO and Founder, Financial Independence Planning, LLC.

Harry Keller CFP®, ChFC, CLU, MBA is the CEO and founder of Financial Independence Planning, LLC. After graduation, Harry joined Arthur Anderson as an auditor. He earned his CPA in 1979. In 1982, Harry launched his own financial planning. Since then, Harry has conducted financial planning seminars for client and trained over a hundred representatives. He has received numerous awards for leadership and for client services. In addition, Harry has extensive tax and financial services training. In addition to being a Certified Financial Planner (CFP®), Harry has received the Chartered Financial Consultant and Chartered Life Underwriter designations from the American College. He has a Master's degree in finance and management, with honors, from Drexel University and a Bachelor of Science, with high distinction and honors in

accounting, from Penn State University. Harry is a member of the Financial Planning Association, the Philadelphia and Montgomery County Estate Planning Councils.

ıg(Frank) Li, PhD, President, Alliance Pharma

g Li, Ph.D. is president and one of the founders of Alliance Pharma. He ained his Ph.D. in Bioanalytical Chemistry jointly from Canadian Doping ıtrol Centre and Concordia University. Subsequently he conducted post-toral training in Biomedical Mass Spectrometry Facility at Mayo Clinic. thermore, Dr. Li also has a BS in Pharmacy and a MS in Medicinal Chemistry. Professionally, he has held responsible roles in the area of drug discovery metabolism at Phoenix International (a major CRO), in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GSK Pharmaceuticals and in the Drug Metabolism group at Cephalon (Now Teva). Dr. Li has extensive DMPK experience in both the drug discovery and development. He is a recognized expert in the field of bioanalysis and DMPK. He has more than 20 years working experience in CRO, pharmaceutical and biotech industries. Under his team's leadership, Alliance Pharma was recognized as:

2014 — *The Philadelphia 100* ® Fastest Growing Companies

2015 — *The Philadelphia 100* ® Fastest Growing Companies

2016 — *SmartCEO's* Future 50 Companies

2017 — *SmartCEO's* Future 50 Companies

Simon Li, MD, PhD, Chief Medical Officer, Vice President of CSPC Pharma

Dr. Li has over 20 years of R&D experience obtained in US and China. Dr. Li has worked in US for 15 years in several companies including Eli Lilly, Bayer, Pharmacia, and Roche on a variety of programs. He has led near 10 clinical programs and obtained NDA approval from the FDA for one of them. Dr. Li has extensive experience on global drug development, clinical protocol development and trial management, project management, site monitoring and CRO management, regulatory affairs and submission, licensing, interactions with KOLs and VCs, etc.

Dr. Li has then worked in Beijing to help Bayer to establish a global development center. He was in charge of clinical development for anti-diabetic and antibiotic drugs in China and AP. He has successfully led the team to obtain CTA approval via Green Channel for an antibiotic drug and conduct a pivotal trial in China/AP for approval of a skin indication. He has also led global teams to develop several life cycle management products for China/AP. Thus, Dr. Li has accumulated rich hands-on experience on clinical research in China and CFDA regulation.

Dr. Li has established a clinical research platform in US from scratch. Under his leadership, his team has completed over 10 clinical studies and reached agreement with the FDA on NDA submission via 505 b(2) for 2 projects. He is currently leading a team to prepare a NDA submission and product

launch in US. He has interacted with the CFDA to change its regulation by introducing FDA regulation and US practice, and is currently working with EU regulatory agencies. He was also involved in M&A target evaluation and preparation for IPO in HK market.

Jie Liu, MBA, Managing Director, New York Office, Torreya Partners

Jie is a seasoned business development professional and has completed over 25 transactions in licensing, asset sales, co-promotion and M&A. He brings significant experiences and expertise in generics and specialty pharma.

Prior to joining Torreya, Jie was Vice President, Business Development & Licensing at Heritage Pharma, a subsidiary of Emcure Pharmaceuticals. Previously he was Senior Director, Global Business Development at Teva. Jie worked as Senior Director, Business Development at Auxilium and Director of Business Development at Cephalon.

Some notable transactions prior to joining Torreya includes Teva acquisition of Auspex for $3.5B in equity value; Teva's acquisition of Labrys Biologics for up to $825M ($200M upfront); Teva's collaboration with Microchips in implantable medical device for $35M in equity investment and technology access fee; Testim co-promote between Auxilium and GSK, Provigil co-promote between Cephalon and Takeda; Cephalon's $350M stem cell deal with Mesoblast for $130M upfront and $220M equity stake; Cephalon's acquisition of ChemGenex for $231M and Cephlaon's acquisition of Salmedix for $160.

Jie is a native Mandarin speaker and received his undergraduate degree from Tianjin University in China. Jie is a licensed Speech Language Pathologist in the US. He holds an MBA in Healthcare from the Wharton School at University of Pennsylvania.

Patrick Liu, MD, PhD, Vice President, Biologics R&D and Head of Global Bioassays and Technology, Teva Pharmaceuticals

Patrick Liu, MD, PhD, is Vice President, Biologics R&D and the Head of Global Bioassays and Technology at Teva Pharmaceuticals. As a global head across countries, he leads a biologics development team with focus on product biological and immunological characterization, PK/PD bioanalytics and immunogenicity assessment for both innovative biologics and biosimilars development.

Prior to joining Teva in 2011, Dr. Liu was a Director with increasing responsibilities at Tanox, Inc. and Genentech/Roche playing a leadership role in R&D for the development and commercialization of biological new molecule entities (NMEs) in the therapeutic areas of oncology, hematology, immunology, allergy and infectious diseases. He contributed to the success of developing multiple blockbuster therapeutics including Lonquex, Granix, Copaxone, Avastin, Lucentis, Herceptin, Perjeta and Xolair, He also filed numerous patent applications and wrote many publications. Dr. Liu has practiced medicine, specializing in Endocrinology and holds a Ph.D. in Molecular Biology.

Zhiping Liu, JD, Partner, Liu, Zheng, Chen & Hoffman LLP

Mr. Zhiping Liu focuses his practice in corporate transactions, concentrating in venture capital funding for start-up companies, mergers and acquisitions and general corporate governance matters. Mr. Liu has experience assisting clients in structuring and consummating over 100 corporate transactions totaling over $7 billion in value, including mergers, acquisitions, financings, restructurings and corporate reorganizations. Mr. Liu received his JD from NYU Law School and practiced for about 7 years with major Wall Street and Silicon Valley law firms before founding Liu, Zheng, Chen & Hoffman LLP, a boutique corporate and intellectual property law firm.

Henry Lu, PhD, Vice President and Head of Biology at Wuxi AppTec

Henry Lu is VP and Head of Biology at Wuxi AppTec. He received his Ph.D. from the Shanghai Institute of Biochemistry and postdoctoral training in RIKEN, Japan and SUNY Stony Brook, USA. Prior to joining WuXi AppTec in 2009, he worked as a biomedical researcher in the SF Bay Area from 1995 to 2009, including as principal scientist at Chiron Corporation (now Novartis), senior director at Rigel Pharmaceuticals, and an adjunct associate professor at the Department of Neurology, UCSF. Under his management, the WuXi Biology team has established an open platform capable of supporting target discovery and validation, assay development and assay transfer, routine screening for SAR support, HTS and HCS, and compound profiling. In addition, WuXi Biology provides pharmacology and PK/PD services for a variety of therapeutic areas such as CVM, CNS, Pain, Respiratory disorders, fibrosis, and etc. In 2016, the WuXi biology platform enabled R&D for more than 230 pharmaceutical, biotech, and academic clients globally.

Jiazhong (Jason) Luo, JD, PhD, Patent Attorney, Duane Morris LLP

Jiazhong (Jason) Luo, JD, PhD, is a registered patent attorney. He practices in the area of intellectual property focusing on all aspects of patent law, including patent prosecution, due diligence, opinion, and litigation. Dr. Luo has represented clients in patent prosecutions in the areas including but not limited to chemistry, pharmaceuticals, polymer science, material science, nanotechnology, semiconductors, electronic and optoelectronic devices, and medical devices. He has performed analyses and drafted opinions on patentability, freedom-to-operate (FTO), non-infringement, and invalidity; and has worked on patent litigation (including ANDA opinions and litigation) and inter partes review (IPR) cases. Dr. Luo has also worked on matters involving corporate, trademark, immigration and citizenship.

Dr. Luo has more than a decade of industry experience in materials science, chemistry and nanotechnologies. He developed and commercialized several new technologies and products. Dr. Luo is an inventor of eleven U.S.-issued patents. He has also authored fifteen peer-reviewed research papers and three legal papers.

Dr. Luo earned a PhD and an MS in Materials Science and Engineering from The Ohio State University. He also holds an M.S. in Polymer Chemistry and Physics and a B.S. in Chemistry from Nankai University. Dr. Luo graduated from Temple University Beasley School of Law with a JD, *cum laude*, in 2013, and received the Robert C. Podwil Memorial Prize. He was also an editor for *Temple Journal of Science, Technology & Environmental Law*.

Michelle Mack, MS, Director of Scientific Engagement, Crown Bioscience

Michelle Mack, Director of Scientific Engagement at Crown Bioscience brings 15 years of previous Oncology R & D experience from Pfizer Inc., where she was a Senior Scientist in the Oncology Research Unit and served as a research project leader on oncology therapeutic programs. At Pfizer, she led cross-functional teams exploring approaches that included: small-molecule inhibitors, antibody drug conjugates and nanoparticle based therapeutics. Michelle's scientific expertise span's the preclinical and translational space for multiple solid and hematological tumor indications. Throughout her professional career, Michelle has worked in Oncology, Immunology and Immuno-Oncology therapeutic areas. She has several high-impact peer-reviewed publications and has led discussions at multiple scientific conferences. Michelle obtained her undergraduate degree from Rochester Institute of Technology, Rochester, NY. She then received her MS in microbiology and is currently completing her PhD in molecular biology from Seton Hall University.

Mike Malefakis, MIA, Associate Vice Dean, Aresty Institute of Executive Education, Wharton School, University of Pennsylvania

Mike Malefakis is Associate Vice Dean, Aresty Institute of Executive Education at The Wharton School, University of Pennsylvania. Wharton Executive Education attracts over 9,000 executives from around the world to in-person programs each year and reaches another 50,000 through online programs.

Mike joined Wharton on January 30th after serving six years as Associate Dean of Executive Education at Columbia Business School. At Columbia Mike led the team that grew revenue more than 54% over six years by working closely with faculty and staff to renew the portfolio of courses offered. Mike started online programs at Columbia as part of Executive Education's mix of offerings to better serve corporate clients.

Prior to Columbia, Mike served as Director of Executive Education at the University of Chicago Booth School of Business. Mike was responsible for overall strategy, P&L, and marketing of both open and custom programs. He also launched programs in Barcelona, Singapore and London as part of Booth's global outreach. He joined Chicago's Executive Education when it was at start-up phase and helped guide growth of 700% over 11 years to position Chicago as a respected global provider of Executive Education.

Earlier in his career Mike worked as the Director of the Executive Education Center at the Institutio Centroamericano de Adminsitracion de Empreses in San Jose, Costa Rica. While there, Mike

managed a 12-country executive education program that provided training to more than 3,800 executives annually. He started in the field of executive education at the University of Michigan as an Assistant Director when the University of Michigan was ranked #1 in Executive Education by *Business Week*.

Mike holds a Master of International Affairs from Columbia and a BA in Social Science from the University of Michigan. Mike served as Chairman of the Board of UNICON, the International Association of University Based Executive Education.

Li Mao, MD, Vice President, Head of the Johnson & Johnson China Lung Cancer Center

Li Mao, MD, is a Vice President and Head of the Johnson & Johnson China Lung Cancer Center. He joins J & J from the University of Maryland School of Dentistry, where most recently he served as Professor and Chair, Department of Oncology and Diagnostic Sciences, and Associate Dean for Research. He also served as the Co-Leader of the Experimental Therapeutics Program in the Marlene and Stewart Greenebaum Cancer Center. Before that, he was a Professor in the Department of Thoracic and Head & Neck Medical Oncology at the University of Texas MD Anderson Cancer Center, where he remains as an Adjunct Professor. In the past 20 years, he and his research team have made seminal contributions in cancer research including the first demonstration of genetic biomarkers for cancer diagnosis/risk assessment using common body fluids. He is a leader in the field of translational cancer research focusing on precision medicine for upper areodigestive tract malignancies and has helped to advance understanding of carcinogenic processes of tobacco-related upper aerodigestive tract cancers. In addition, he played a critical role in several large scale multi-investigator and institution research programs. He has authored or co-authored more than 180 peer-reviewed publications cited more than 10,000 times.

Jay Mei, MD, PhD, Founder and CEO, Antengene Corporation

Jay Mei, MD, PhD, founder and CEO of Antengene Corporation, a clinical stage biopharmaceutical company based in China. Prior to founding the new start-up, Jay was an executive medical director at Celgene Corporation, which is now the first drug development business partner of Antengene. After eight and a half years at Celgene, Jay founded Antengene with clinical stage molecules licensed from Celgene where he was previously the clinical lead for the development of several oncology drugs, including Revlimid and Enasidenib. Jay was responsible for the global clinical studies of these agents, and also initiated the registration effort and trials in China for Revlimid since 2008. Jay led the studies that resulted in the approval of Revlimid by the CFDA in early 2013. Prior to Celgene, Jay was a global clinical program head at Novartis Oncology, and a clinical research physician and associate director at J&J leading cancer drug discovery and development. Jay was trained at US National Cancer Institute from 1993-2001

after his medical and PhD education. Jay attended the SAPA inaugural conference at the Rutgers university campus in 1992.

Thomas J. Parker, JD, Partner, Alston & Bird LLP

Thomas J. Parker is the co-founder of the Hatch-Waxman Litigation Group at Alston & Bird.

Tom has over 25 years of experience representing clients in patent-related matters. He focuses his practice on trial and appellate litigation, including Hatch–Waxman patent infringement and related regulatory actions. He serves as lead trial counsel for major pharmaceutical companies in both traditional and Hatch–Waxman litigations. Tom serves as lead counsel in *inter partes* review proceedings before the Patent Trial and Appeal Board.

He regularly counsels clients on matters relating to patent prosecution, interferences, freedom to operate and licensing in a host of areas, including pharmaceuticals, chemical compositions and biotechnology, as well as medical devices. He is registered to practice before the U.S. Patent and Trademark Office.

Tom has extensive experience in matters involving the interaction among the patent and FDA laws in the drug approval process relating to Abbreviated New Drug Application (ANDA) and Section 505(b)(2) filings under the Hatch–Waxman Act, as well as biosimilar drug applications filed under the Biologics Price Competition and Innovation Act (BPCIA).

Tom has an advanced science degree and more than four years of research experience, including work as a research scientist in microbiology and genetics. In particular, he worked as an associate scientist in human genetics and immunogenetics for Miles Pharmaceuticals Inc. in West Haven, Connecticut.

Gunaretnam(Guna) Rajagopal, PhD, Global Head of Computational Sciences within Discovery Sciences, Janssen R&D

Guna is currently the Global Head of Computational Sciences within Discovery Sciences at Janssen R&D. His team is mandated to provide "big data analytics", high performance computing and genetics/genomics expertise to address and support the evolving need of researchers to identify and validate safe and effective large and small molecule drugs. He is a member of the Discovery Sciences Board, Chair of the R&D Informatics Committee and the J&J Real World Evidence (RWE) Senior Leadership team. Before joining Janssen, Guna was at the Rutgers Cancer Institute of New Jersey (CINJ), a NCI-designated Comprehensive Cancer Center, as Executive Director (Bioinformatics) and an Adjunct Professor of Radiation Oncology at the Robert Wood Johnson Medical School. In addition to providing Bioinformatics support to researchers in Rutgers and Princeton, with funding from the state of New Jersey and the Robert Wood Johnson Foundation, his team deployed inter-operable EMR's that increases operational efficiency and improved

treatment outcomes. The data collected was used to catalyze the Personalized Medicine Initiative at CINJ. He was a member of the Simons Center for Systems Biology at the Institute for Advanced Study, Princeton working with Arnie Levine to develop systems-level approaches to unravel the complex biology of ageing and the genetics of complex diseases such as cancer and autism. Prior to joining CINJ, he was the founding Executive Director of the ASTAR Bioinformatics Institute (BII) at the BIOPOLIS, Singapore. He led the team that developed and deployed state-of-the-art cyber-infrastructure, bioinformatics and high performance computing capabilities to support public and Industry-led research institutes co-located at the BIOPOLIS. He initiated a postgraduate program in Bioinformatics with the National University of Singapore, many of whose graduates have now received PhD's from world-class universities. Prior to his appointment in Singapore, he spent twelve years at the University of Cambridge, United Kingdom. He was an Assistant Director of Research at the Cavendish Laboratory, where he conducted research and supervised PhD students and postdocs in theoretical and computational physics funded by grants from the UK, EU and Hitachi. He was also a Fellow and Director of Studies in Physics at Jesus College, Cambridge. Guna received his PhD in theoretical physics from the Georgia Institute of Technology and his undergraduate and MSc (in Particle Physics) from the University of Malaya. He is a member of various professional scientific organizations and has sat on research funding bodies in the US, UK, Ireland, Holland, Japan, Malaysia, Singapore, and European Union. He is a visiting professor with the University of Malaya Cancer Research Institute and was a scientific consultant to Unilever, Johnson & Johnson, Novartis AG and Daiichi-Sankyo. He was recently appointed to the Scientific Advisory Board of IMEC, Belgium (to advice on digital technologies in healthcare delivery) and to the Panel of Experts to the European Commission (to advice on the Digital Agenda for Europe Horizon 2020 Flagship Initiative).

Paul Savidge, JD, MBA, Senior Regulatory Counsel, Spark Therapeutics

Paul Savidge is senior regulatory counsel at Spark Therapeutics, a leading gene therapy company, where he provides counsel on a broad range of issues, including those related to drug development and commercialization. Prior to joining Spark, Paul was senior vice president and deputy general counsel at Bristol-Myers Squibb and led the legal groups assigned to the company's global commercial and research organizations. While at BMS, Paul also headed the global labeling and promotion compliance teams. Prior to BMS, Paul held positions in the US and European legal departments at Merck. He began his legal career practicing trade regulation law at the Morgan, Lewis firm in Washington, DC.

Paul received his JD from Washington & Lee University, an MBA from the Kellogg School of Management at Northwestern University and a BSFS from Georgetown University's School of Foreign Service.

Bin Shi, PhD, President, SAPA-GP; Head of External R&D/Licensing, Amgen Asia R&D Center

Dr. Bin Shi joins Amgen Asia R&D Center in September 2016 serving as Head of External R&D and Licensing to leverage wide external scientific and technology expertise in China and Asian Pacific areas to advance and complement Amgen's global internal effort in discovery of breakthrough medicines. Before that, Bin has been working in the pharmaceutical industries in US for more than 18 years, overseeing anti-cancer, anti-viral and vaccine drug discovery and development. She is a Research Fellow and Associate Principle Scientist in Pharmacology Department at Merck West Point, PA. She has been an active member of AACR (American Association of Cancer Research) since 2006 and a member of NSH (National Society of Histotechnology). Bin has published more than 40 papers, abstracts and patents in reputed journals including JBC, Cancer Research etc, serving as the first and corresponding author, serving as an invited reviewer for eight peer reviewed journals, editorial board member and an invited speaker at several conferences. She is also actively involved in community services, including Lead of of LINK at Merck to leverage internal networking, knowledge and communication, and Liaison of LINK and Merck Polytechnology training Institution (MPI). Bin is a lifetime SAPA member, and serves in the senior leadership team (SLT) of SAPA-GP with increased responsibility: Executive Council, General Secretary, VP of Public Affairs, Communication and Outreach, President-elect (2015-2016) and President (2016-2017). Most recently Bin is elected as President of SAPA-China (2017-2019). Bin completed her PhD at Thomas Jefferson University in Philadelphia, her Master of Science degree at State University of New York (SUNY) in Syracuse, and her Bachelor of Science degree at Nankai University in Tianjin China.

Huabin Sun, MD, Medical Safety Officer/Director, Global Medical Safety, Janssen R&D

Huabin has over 16 years of pharmaceutical experience including 3 years in drug discovery, 7 years in pre-clinical safety and 6 years in clinical safety. Huabin currently is a Medical Safety Officer in Global Medical Safety of JNJ. Prior to this, Huabin is a Medical Director in Global Pharmacovigilance and Epidemiology of BMS. During past 10 years, Huabin has been involved in pharmacovigilance activities of several later stage development or marketed products, including Brivanib, Nivolumab, EPREX, and Daratumumab.

Lauren Swartz, BA, Senior Director of International Business Investment, Department of Commerce, City of Philadelphia

In her role as Director of International Business Investment for the City of Philadelphia under the Department of Commerce, Lauren Swartz works with international businesses to create foreign direct investment in Philadelphia. She also supports initiatives to grow Philadelphia's exports, helping to create jobs and strengthen the local economy. She plays a key role laying the strategy for Philadelphia's

international business development, hosting delegations from abroad, and representing the City of Philadelphia.

Previously Lauren served as the Deputy Director at the non-profit trade association, Food Export USA – Northeast, working with promote exports in over 40 countries around the world. Funded by USDA, this public-private partnership produced over $500 million in export sales annually. Lauren also has experience running her own consulting firm specializing in international project management and food marketing. She also worked in Copenhagen, Denmark at an international university where she facilitated programs for students of European politics, business and economics.

Lauren is a Fellow of the Leadership Philadelphia Core Class of 2016. She is a member Toastmasters International and member of the Board of Directors of the non-profit Women Against Abuse in Philadelphia. She earned a BA in Communications at Randolph-Macon Woman's College with minors in Business Economics, Spanish and Philosophy. She speaks Danish and some Spanish and has traveled for work and pleasure to over 25 countries. She lives in South Philadelphia with her family.

Weikang Tao, PhD, CEO of R&D Centers, Vice President, Jiangsu Hengrui Medicine Co., Ltd.

Dr. Weikang Tao has served as vice president of Jiangsu Hengrui Medicine Co., LTD. and CEO of R&D Centers since Feb. 2014. In this position, he has led the R&D of innovative therapeutics, ranging from small molecule drugs, therapeutic antibodies and peptides to antibody-drug conjugates and discovered and developed several small molecule drugs and biologics into clinical trials both in China and in the US. Formerly, he served as vice president and the head of biology and pharmacology at Shanghai Chempartner Co., Ltd, a publicly traded company at that time, taking charge of the departments of biology, pharmacology, pathology and translational medicine and overseeing drug R&D programs in different therapeutic areas in collaboration with multiple global pharmaceutical companies and biotech. From 2000 to 2012, he conducted drug R&D at Merck & Co., Inc. in the US as a project leader and functional head, where he led a number of projects and delivered several compounds into clinical Phase II trials. Dr. Tao has published multiple research papers in premier life science journals and he is the holder of multiple issued and pending patents in drug discovery. He obtained a PhD degree in Molecular & Cell Biology from University of Medicine & Dentistry of New Jersey in the US. He was a post-doctoral fellow in cancer cell biology at Princeton University.

Xin Tao, JD, Senior Associate, Hogan Lovells US LLP

With a working knowledge of regulatory requirements and a strong understanding of life science, Xin Tao works closely with clients in the food and drug industry to navigate the evolving federal and state regulatory environments and develop innovative regulatory strategies to commercialize

products made with emerging technologies.

Xin's background in life science (biochemistry and biophysics) assists him in his science-based food and drug law practices. Xin advises clients on food and drug law with a particular focus on novel food and dietary ingredients, biotechnology, FDA cGMP compliance, ingredient labeling, and California's Proposition 65. Xin's unique ability in understanding and interpreting the complex scientific issues as they relate to the governing regulatory requirements helps clients with all phases of the product development, manufacturing, and marketing. He is also increasingly expanding his expertise of USDA's organic regulatory regime as it pertains to his clients.

Xin has helped numerous food, dietary supplement, and pharmaceutical companies evaluate the need for marketing approval from the U.S. Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA), and the Environmental Protection Agency (EPA). He also pursues clearance or pre-market approval (e.g., food additive petition, GRAS notice, NDI notï¨cation) when necessary and responds to FDA enforcement activities including Warning Letters and Import Alerts. Xin has advised numerous companies on issues relating to the advertising and promoting of products including the Federal Trade Commission (FTC)'s claim substantiation standards. Xin also has vast experience with FDA and USDA due diligence investigations for companies' subject to takeover or merger activity.

Xin is very actively involved in a number of organizations that serve Chinese legal and life science professionals in the Washington region, including the Sino-American Pharmaceutical Professionals Association and Washington DC Chinese Legal Association. Xin is a frequent speaker and contributor to industry publications both in the U.S. and China. He is adept at assisting both Chinese food and drug companies doing business in the U.S. and U.S. clients doing business in China.

During law school, Xin worked as a regulatory food scientist and also served as an executive editor of the Georgetown Environmental Law Review.

Joseph Tarnowski, PhD, Senior Vice President, Cell and Gene Therapy Platforms, PTS, R&D, GlaxoSmithKline

Joseph Tarnowski is Senior Vice President of Cell and Gene Therapy Platforms, PTS, R&D at GlaxoSmithKline (GSK). Before joining GSK in June, 2010, Joe was the Senior Vice President, Biologics Manufacturing and Process Development in the Technical Operations division of Bristol-Myers Squibb Co. in New Brunswick, NJ. Joe was responsible for building the manufacturing capabilities needed to supply the company's biologic medicines to worldwide markets, including the construction of the company's new $750 million large-scale multi-product bulk biologics manufacturing facility in Devens, Massachusetts, and the integration of Medarex, Inc. He has spent over 35 years in the pharmaceutical industry focused primarily on the research, development, registration and commercialization of biopharmaceutical products made using recombinant DNA technology. He holds 13 patents and has several patent applications pending for biologic products.

Joe earned a BS degree in Chemistry from Southeast Missouri State University and a PhD degree in Biochemistry from the University of Tennessee Center for the Health Sciences. After receiving his PhD, Joe was awarded a post-doctoral fellowship in Molecular Biology at the prestigious Roche Institute of Molecular Biology, in Nutley, NJ.

Following his fellowship, Joe was hired to be a senior scientist to develop the large-scale protein purification processes necessary for the manufacture of Recombinant Protein Therapeutics. Interferon Sciences, Inc. recruited Dr. Tarnowski from Hoffman-LaRoche, and he later held senior positions at Scios (acquired by Johnson & Johnson), CellPro, Inc. (cell therapeutics company), and ImClone Systems Incorporated (acquired by Eli Lilly).

While at ImClone Systems, he grew the company's Branchburg, NJ Campus from one building on six acres to seven buildings on nearly 50 acres. After the completion of its second manufacturing plant in 2005, ImClone Systems was one the world's largest mammalian cell culture manufacturers.

Joe has held critical roles in the manufacturing, process development, registration, and launch of several FDA and internationally approved human therapeutic products, including Roferon® A, Alpheron N®, Fiblast® Spray, CEPRATE® SC Stem Cell Concentration System, Natrecor®, Erbitux® Orencia®, Yervoy®, Nulojix®, Eperzan®/Tanzeum®, Nucala®, and Strimvelis™. He has a thorough understanding of the biologics drug registration process and has had extensive experience in developing the Chemistry, Manufacturing and Controls (CMC) sections for many Investigational New Drug and Biologics License Applications.

Dengxi Wang, MS, Deputy Secretary, CPC Xinxiang Municipal Committee and Mayor, Xinxiang Municipal People's Government

Mr. Dengxi Wang was born in June, 1963 in Tangyin County, Henan Province. Mr. Wang holds a Postgraduate Degree from The Party School of the CPC Henan Province Committee and multiple certificates including Certified Economist, Certified Safety Engineer and Advanced Technical Consultant.

Mr. Wang's previous positions include: Deputy Director and Member of the Party Leadership Group of Henan Province Administration of Work Safety; Member of the Standing Committee and Head of Publicity of the CPC Xuchang Municipal Committee; Vice Mayor and Member of the Party Leadership Group of Xuchang Municipal Government; Deputy Secretary-General and Member of the General Office Party Leadership Group of Henan Provincial People's Government.

Mr. Wang currently serves as the Deputy Secretary of the CPC Xinxiang Municipal Committee and the Mayor of Xinxiang Municipal People's Government.

王登喜，中共河南省新乡市委副书记、新乡市人民政府市长

王登喜，男，汉族，1963 年 6 月生，河南省汤阴县人。河南省委党校研究生学历，经济师、注册安全工程师、注册高级咨询师。

历任河南省安全生产监督管理局副局长、党组成员；中共河南省许昌市委常委、宣传部部长，市政府副市长、党组成员；河南省人民政府副秘书长、办公厅党组成员。

现任中共河南省新乡市委副书记、新乡市人民政府市长。

Jim Wang, PhD, MBA, Head of Regulatory Affairs Strategy at Spark Therapeutics

Dr. Jim Wang is head of regulatory affairs strategy at Spark Therapeutics, a leading gene therapy company based in Philadelphia. He has more than 13 years of global regulatory experience managing full-spectrum drug development, marketing applications, and regulatory approvals for biologics, gene therapy, small molecules, and device drug combination products. In his current role, Jim is managing global health authority interactions, submission, and potential approval for the company lead product candidate, voretigene neparvovec. He is leading a multidisciplinary team to develop company product labeling, risk management plans, and regulatory filing documents. Previously, Jim was an executive director of global regulatory affairs at Shire. He was responsible for implementing a consolidated global regulatory strategy to secure approval and market access for rare disease biological products through all development phases and life-cycle management. Prior to Shire, Jim was a senior director at Novo Nordisk responsible for global health authority interactions (e.g. FDA, EMA, PMDA, COFEPRIS, Health Canada, and China's FDA), marketing applications (e.g. NDA, MAA, NDS, etc.), and approvals for Saxenda®. He also held senior regulatory positions at BMS, Sanofi, and Wyeth.

Jim received his PhD from the University of Illinois at Champaign-Urbana, MBA from Pennsylvania State University, and a BS from Jilin University in China.

Jingang Wang, EMBA, CEO, CoSci Med-Tech Co.,Ltd.

Mr. Wang Jingang, senior pharmaceutical engineer, founder and General Manager of CoSci Med-Tech Co., Ltd., who trusted science and technology as the leading solutions to pharma industry and human society. He and his colleagues thus focus on innovative Drug Delivery Systems and high quality formulations, and have established 13 DDS technology platforms and released dozens of high-end generics to the industry.

He was awarded for: "outstanding contribution individual of Zhongguancun Science and Technology Park 20 anniversary", 2009; "50 outstanding innovators for business field in China", 2012;

As team leader, he led the national projects: "11th five-year plan, major pharma innovation project" "12th five-year plan, major pharma innovation project"

He is assigned as: Member of Pharmaceutical Engineering of Chinese Pharmaceutical Association; Expert reviewer of "12th five-year plan, major pharma innovation project"; Vice president of 12th five-year plan, major pharma innovation project

Jingyi Wang, MD, PhD, President of Kelun Pharmaceutical Research Institute

Dr. Wang current is the President of Kelun Pharmaceutical Research Institute (PRI). He is also the Chief Scientific Officer and Depute General Manager of Sichuan Kelun Pharmaceutical Co., Ltd. Dr. Wang joined Kelun in 2012 as the President of Kelun PRI. Under his leadership, Kelun PRI has evolved from less than 100 employees to more than 1800 employees with annual R&D budget exceeding 0.6 billion Yuan in 2016. Kelun PRI has established capacity in four areas, Generic Drugs, Innovative Small Molecules, Biology Drugs, and New Drug Delivery Systems. During past four years, Kelun PRI has initiated more than 270 projects on generic drugs and more than 60 innovative drug projects, covering areas of oncology, cardiovascular and metabolic disease, immunology and infectious disease. Prior to joining Kelun, Dr. Wang was the President of Qilu Pharmaceutical Research Institute from 2002 to 2012. During his 10-year tenure in Qilu Pharmaceutical Co., LTD, Dr. Wang led the Qilu's R&D organization becoming one of the best drug discovery and development organizations in China, including marketing approval of more than 30 drugs, some of them with annual revenue more than a billion Yuen. Dr. Wang graduated from China Medical University and obtained his medical degree in 1982. He earned a PhD in molecular biology and virology from Fourth Military Medical University in 1991. He was a visiting scholar of Rickettsiosis Research and Collaboration Center (France) of World Health Organization (WHO) in 1995.He moved to United States and started his postdoctoral research at University of Arkansas in 1996 and subsequently became an Assistant Professor in Arkansas Cancer Research Center in 2000.

Jun Wang, PhD, Vice President of Biology, Shanghai Medicilon, Inc.

Dr. Jun Wang is a Vice President of Biology at Shanghai Medicilon.Inc. Prior to Medicilon, Dr. Wang was a Vice President and Head of Biology at Sundia MediTech. Before joining Sundia, Dr. Wang had served at Merck Sharp & Dohme Corp. for about 9 years leading multiple drug-discovery programs on principles of food-animal growth promotion, infectious diseases, diabetics and cardiovascular diseases. Prior to Merck, Dr. Wang worked at a biotech company-Molecumetics in Seattle as a head of biology and served as an assistant & affiliate associate professor in University of Texas Southwestern Medical Center and University of Washington for 5 years. Dr. Wang has published numerous papers as the corresponding author in leading scientific journals (Nature, PNAS, JBC etc). Dr. Wang has been invited by many organizations including University of Cambridge, Royal Society of Chemistry, Naito Foundation etc. for presentations on his discovery of novel candidates of antibiotics (Platensimycin and Platencin). Dr Wang is also serving as an editorial board member for three international journals.

Dr. Wang got his B.S. in biophysics from Fudan University and received his Ph.D. in the area of molecular biology and biochemistry from Kobe University (Japan). Post-doc training was followed in the Department of Pharmacology at UT Southwestern Medical Center (Dallas).

William(Bill) Wang, PhD, Executive Director, Clinical Safety Statistics, Biostatistics and Research Decision Sciences(BARDS), Merck Research Laboratories

Dr. William (Bill) Wang is an executive director, clinical safety statistics, in the department of Biostatistics and Research Decision Sciences (BARDS), Merck Research Laboratories. He has 24 years of experience in the pharmaceutical industry, with expertise and research publications in statistical design, analysis, clinical data management and their technology enablement. During his 17+ year tenure at Merck, he supported regulatory filings in multiple therapeutic areas and established the BARDS Asia Pacific operation (2007-2014).

Since 2010, he has served on the DIA China Regional Advisory Board and the DIA's Global Community Leadership Council (CLC). He was the founding chair of the DIA China Statistics Community and its annual Quantitative Science Forum (QSF). He was a recipient of the DIA China outstanding service award in 2012 and DIA Global Inspire Award in 2017. He is currently chairing an ASA safety monitoring working group, and a deputy topics-leader in the ICH E17 working group on multi-regional clinical trials.

Gary D. Wu, MD, Ferdinand G. Weisbrod Professor in Gastroenterology, University of Pennsylvania, School of Medicine

Dr. Wu is the Ferdinand G. Weisbrod Professor in Gastroenterology at the Perelman School of Medicine at the University of Pennsylvania where he is the Associate Chief for Research in the Division of Gastroenterology and is also the Associate Director of the Center for Molecular Studies in Digestive and Liver Disease. He was the founding Director and Chair of the Scientific Advisory Board for the American Gastroenterological Association's Center for Gut Microbiome Research and Education and is an elected member of both the American Society for Clinical Investigation and the Association of American Physicians. He has recently been appointed as a co-Director of the Penn-CHOP Microbiome Program. The research programs in the Wu laboratory focus on the mutualistic interactions between the gut microbiota and the host with a particular focus on metabolism.

Zhenhua Wu, PhD, President-Elect, SAPA-GP; Associate Director, GlaxoSmithKline

Dr. Zhenhua Wu is a senior discovery and preclinical development leader with more than 15 years' experience and a deep understanding of the R&D value chain. Zhenhua was recently elected to the President (2017-2018) of Sino-American Pharmaceutical Professional Association-Great Philadelphia (SAPA-GP). He is currently an Associate Director in Neuroscience Therapeutic Area Unit at GlaxoSmithKline, where he serves as a global project leader focusing on therapies for neurodegenerative diseases. He is responsible for directing

virtual drug discovery pipeline through partnering with external groups, such as biotech, academic groups and CROs, toward to proof-of- concept studies. Prior to joining GSK, Zhenhua had worked in various functional areas in Merck & Co. for nearly 10 years where he led various neuroscience projects and delivered three preclinical candidates and served as a global externalization leader in major geographic regions. Zhenhua received his PhD degree in neuroscience from University of Rochester and MS degree in cell biology from Shanghai Institute of Cell Biology, Chinese Academy of Sciences. He has published extensively in the field of neuroscience including publications in prestigious journals such as Nature, Nature Medicine, Neuron and Stroke. He is also a recipient of Hugh Davson Distinguished Award in Neurovascular Biology.

Jijun Xing, PhD, Science and Technology Counselor in Chinese Consulate-General in New York

Dr. Jijun Xing received a bachelor degree of engineering, Tianjing University, a master degree in economics, People's University of China and a PhD in administrative management, Huazhong S&T University. Dr. Xing has years of experience since 1990 in managing and facilitating international scientific and technological cooperation. He served in Chinese Embassies in Norway and the Netherlands, Director of Asia and Africa and Director of Europe in the Chinese Ministry of Science and Technology (MOST). Before taking the current position, Dr. Xing served China Science and Technology Exchange Center as Deputy Director General covering governmental and non-governmental cooperation in science and technology, technology transfer and academic exchanges. His personal academic interest includes low carbon development technologies and low cost health technologies etc. Dr. Xing is now still a strategic evaluation expert for international cooperation under European Horizon 2020 program.

Bangqian Xu, PhD, Chief Operating Officer, Oryza Pharmaceuticals Inc.

Dr. Xu Has over 20 years' experience in bioavailability and bioequivalence of generic product development.

In the past 20 years, Dr. Xu has worked as Manager, Associate Director, Director, and Senior Director at Apotex, Watson Pharmaceuticals, KU/UCB and Qualitest Pharmaceuticals. He has been involved in the design and evaluation of phase I BA/BE studies for a wide variety of dosage forms including oral (IR, ER/DR capsules, tablets, and respiratory tract, etc.), rectal, transdermal, topical, urogenital, and nasal products.

His background includes bio-analysis, pharmacokinetics, BA/BE, clinical endpoints study, statistical analysis, scientific/regulatory affairs. He also has extensive knowledge of FDA/CFDA/HPB/ICH regulations, policies, procedures, drug development guidelines and compliance.

Dr. Xu received doctoral degree from the School of Medicine, University of Oslo, Norway.

Liang Xu, LLM, Parter, Hogan Lovells International

Working as a bilingual lawyer, Liang Xu has advised on many cross-border M&A transactions, both for Western corporations doing business in China, as well as Chinese enterprises (including SOEs and private companies) looking to expand and invest in global markets.

Liang Xu is qualified in China and the New York State in the U.S., and is nominated as one of the Chambers Global leaders in the field of Corporate/M&A in China.

His Representative experiences are as followed:

Representing a Chinese company in acquisition of port assets in Panama for an undisclosed amount.

Representing publically listed Chinese client, Xinjiang Urban Construction (Group) Co., Ltd on its US$1.5 billion reverse takeover by Jiangsu Jinsheng Industrial Co., Ltd., which involves injection of global assets in 12 jurisdictions.

Representing Guangzhou Automobile in its US$ 100 million investment in Uber China.

Representing China Cinda on the acquisition of a real estate development project in Beijing for US$1.6bn. Representing a China based private equity fund in its proposed US$320m investment in a Hollywood movie studio.

Representing a major Chinese e-commerce company in relation to its joint venture in Southeast Asia. Representing KPP in relation to its US$650m acquisition of selected assets from Eastman Kodak Company, including assets and entities in China.

Representing TE Connectivity in its acquisition of two private Chinese companies in Xiamen.

Representing Texas Instruments in acquiring a major Chinese semiconductor manufacturing facility in Chengdu.

Representing ALSTOM in the public takeover of Wuhan Boiler, a company listed on Shenzhen Stock Exchange.

Representing Actavis in its acquisition and disposal of several pharm manufacturing facilities in China.

John Xu, MD, MBA, MS, Senior Vice President of Strategic Alliance, AbPro

Dr. John Xu got his medical degree from Shanghai Medical University (now Fudan medical college) and his Master of Science and MBA degrees from US universities. He has more than 13 years of early drug discovery research experience in BMS and Wyeth in both oncology and CNS areas.

Dr. Xu also had very successful business development experiences for several large CRO companies such as WuXi AppTec, CrownBio and HD Biosciences. During the seven years when he was responsible for global and US business development, he achieved the highest revenue for all the companies he had worked. He had built large network in biotech and pharmaceutical companies both in the US and China.

Currently, Dr. Xu serves as the Senior Vice President of strategic alliance for AbPro, a biotech

company based in Boston. His responsibilities include building strategic partnerships with global biotech and pharmaceutical companies to develop therapeutic bi-specific antibodies.

Stephen Yang, JD, Senior Associate, Alston & Bird LLP

Stephen Yang is a senior associate in Alston & Bird's Intellectual Property Litigation Group.

Steve has worked on a wide range of intellectual property matters, with a focus on patent litigation before U.S. district courts and the U.S. International Trade Commission, particularly Hatch-Waxman and ITC 337 cases. Steve has worked on over thirty Hatch-Waxman cases, obtaining for his clients favorable results resulting in hundreds of millions of dollar in revenue.

Steve also has extensive experience with the regulatory aspects of the drug approval process relating to Abbreviated New Drug Application (ANDA), as well as securing the 180-day generic exclusivity for the first ANDA filer. As an outside litigation attorney, Steve was selected to work as an in-house counsel by his client, a major pharmaceutical company in New Jersey. There, Steve's responsibilities included managing ongoing litigations, product review and design, and contract and agreement negotiations.

During law school, Steve also served as a judicial intern for the Honorable William G. Young of the U.S. District Court for the District of Massachusetts and for the Honorable Robert J. Lynn of the New Hampshire Supreme Court.

Junzhi(John) Yao, PhD, co-founder and CEO, TC Scientific

Dr. Junzhi (John) Yao is co-founder and CEO of TC Scientific, a chemistry centric leading CRO in Edmonton, Alberta Canada.

Dr. Yao co-founded TC Scientific in 2009 and has over 20 years' experience in organic synthesis and the chemical CRO business. Dr. Yao received his PhD degree in chemistry from Wuhan University. After graduation, he joined the Department of Chemistry at Wuhan University in July 1994 as an Assistant Professor. From 1995 to 1997, Dr. Yao worked at Hong Kong University of Science and Technology as a Visiting Scholar. He obtained Postdoctoral Research training at the Department of Chemistry at Southern Methodist University in Dallas, USA from 1997 to 1999 and conducted postdoctoral research at the Department of Chemistry and Faculty of Pharmacy at the University of Manitoba, Canada for from 1999 to 2001.

Dr. Yao joined Medicure Inc. in Winnipeg, Canada as a Research Scientist conducting drug discovery research on cardiovascular diseases and stroke. His contract research experience includes a 3-year collaboration effort with Pfizer. He has worked with wide variety of companies ranging from virtual to large biotech and Pharmaceutical companies.

Mingde Yu, Honorary President and Chair of Expert Committee, China Pharmaceutical Enterprise Association

Mr. Yu has devoted much of his career to drug manufacturing, distribution and management. Prior to his current appointment, Mr. Yu assumed multiple roles in the pharmaceutical industry, including: Scientist, Liaoning Fuxin City Research Institute of Chemical Engineering; Factory Director and Technical Chief, Fuxin City Traditional Chinese Medicine Factory and Fuxin City Pharmaceutical Factory; General Manager of Fuxin City Pharmaceutical Company; Director of Fuxin City Municipal Medicine Administration Bureau; Deputy Director and Director of Liaoning Province FDA; Director of Finance and Market Circulation in China FDA; Director of Pharmacy and Medicine in State Economic and Trade Commission PRC; Deputy Director of the Bureau of Economic Operations; Deputy Director of Economic Operation Bureau of National Development and Reform Commission.

In addition to his current title, Mr. Yu also serves as: Investigator in the Research Center for Global Medicine of Peking University; Vice Chairman of Pharmaceutical and Biopharmaceutical Expert Advisory Board in National Development and Reform Commission; Member of Drug Distribution Expert Committee in Ministry of Commerce, China; Selected Expert for the Thirteenth Five-Year Plan in Ministry of Industry and Information Technology; Selected Expert of the "09 Special Evaluation Group" in Chinese Academy of Engineering; Member in the Expert Advisory Board of National Committee of "Made in China 2025".

于明德，现任中国医药企业管理协会名誉会长、专家委员会主任。

长期从事药品生产、流通管理工作。曾任辽宁省阜新市化工研究所技术员、阜新市中药厂、市制药厂技术科长、厂长，市医药总公司总经理、市医药管理局局长；辽宁省医药管理局副局长、局长；国家医药管理局财务与市场流通司司长；国家经济贸易委员会医药司司长、经济运行局副局长、国家发展与改革委员会经济运行局副局长。

现应邀兼任北京大学国际医药研究中心研究员；国家发展改革委员会生物医药专家咨询委员会付主任；商务部药品流通行业专家委员会专家；工信部十三五专家；中国工程院 09 专项评估组专家；国家《中国制造 2025》咨询委专家。

Dan Zhang, MD, MPH, MA, CEO, Fountain Medical Development Ltd.

Dr. Dan Zhang has more than 15 years of drug development experience. He is the Chairman of Fountain Medical Development Ltd (FMD), a full-service clinical CRO with operations in South East Asia, China, Armenia, and the USA. With more than 500 employees, FMD runs phase I/II/III/IV operations with full support of regulatory affairs, data management and biostatistics, EDC, and pharmacoeconomics operations. FMD has 70 employees in Philadelphia, PA, USA and has filed 15 NDAs in the last 36 months with 11 of them being approved and 4 are pending.

Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc., Vice President at the Quintiles Transnational Corp., a member of Quintiles Executive Operation Committee, and was also the Chairman of the Board for Quintiles Medical Development (Shanghai) Company Ltd. Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device, and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., and CIGNA Health Care.

Over the last 15 years, Dr. Zhang has provided services for the government and academic institutions in China. He is a member of the grant review committee for the National Key Drug Development Fund jointly managed by the Ministry of Science & Technology (MOST) and the National Health and Family Planning Commission of China (NHFPC). He chaired the Bayhelix CFDA working committee and works with the agency on the development of technical guidelines. He was a member of the Overseas Expert Committee on New Drug R&D from MOST. He is the senior consultant to the Chinese Academy of Medical Sciences and Peking Union Medical College. He was also a visiting professor at the Harbin Medical University of China, Nankai University, and Science and Technology University of South China. He is currently a senior consultant to the Chinese Academy of Medical Sciences / Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-American Professional Pharmaceutical Society (SAPA), the President (2006~2007) of the Chinese Biopharmaceutical Association-USA (CBA), a Board of Director of Bayhelix, and is currently Secretary-General of the Association of Thousand Talents Program.

He received his pre-med training from Peking University and received his MD from Peking Union Medical College in China. He continued his study at the Harvard School of Public Health in the US and received an MPH in Health Policy and Management. He then continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his Masters in Healthcare Management in 1998 and is working on his PhD dissertation in the field of health economics and finance.

Ming-Qiang Zhang, PhD, Vice President of Research & Development at Amgen, Head of Amgen Asia R&D Center in Shanghai, China

Dr Ming-Qiang Zhang is corporate Vice President of Research & Development at Amgen, and Head of Amgen Asia R&D Center in Shanghai, China. He has more than 24 years of R&D experience and led the discovery of multiple candidate drugs progressed to approval or clinical development for the treatment of CNS, cancer, inflammatory and infectious diseases, including Merck's first-in-class muscle relaxant reversing agent BRIDION® (*sugammadex*) which is approved on market in US, Europe and Japan. BRIDION® is nominated for The Prix Galien, the equivalent of the Nobel Prize in biopharmaceutical and medical technology research. He is the (co)author/(co)inventor of more than 100 scientific publications/patents, a Fellow of the British Royal Society of Chemistry and the Associate Editor (Asia Pacific) of *MedChemComm*, the official journal of the European Federation for Medicinal Chemistry. His scientific achievement has been recognized by a number of other prestigious awards including the Malcolm Campbell Memorial Prize (2007) and the Nexxus Life Science Award for Innovation (2008).

Prior to joining Amgen, Dr Zhang held a series of R&D leadership roles with increasing responsibilities in various companies ranging from biotech, specialty pharma to big multi-national companies. He was corporate Vice President and Head of Asia Pacific R&D at Merck Sharp & Dohme (Merck & Co.), and served as the founding General Manager of MSD R&D (China) Co. Ltd. He helped Merck establish one of the largest multi-disciplinary R&D centers in China. Before Merck, he was Chief Technology Officer and Head of External Research at F Hoffmann-La Roche's Pharma Research and Early Development (pRED) China. He also co-founded ViroChem Pharma Inc. in Montreal, Canada, which discovered the potential best-in- class non-nucleoside HCV polymerase inhibitor and was acquired by Vertex in March 2009 for US$380 million.

Yudan Zhang, CPA, MSA, Senior Manager, Transaction Advisory Services, EY

Yudan has experience of over 10 years on both buy and sell side M&A transactions ranging from $20M to $30B for private equity and corporate clients with financial due diligence, negotiation assistance, data preparation and analysis.

She assisted and coordinated outbound M&As by Chinese corporations in the U.S., Europe and Asia across difference industries, as well as outbound M&As by American clients into Asia. Her main Chinese clients with investments in the Healthcare / Life Sciences sector are: HNA Group, Wanda Group, Sinocare, etc.

Her experience includes add-on acquisitions, carve-out transactions, leveraged buyouts, public-to-private transactions, cross-border, accounting consultations and other contract issues for both financial investors and strategic acquirers.

Sean Zhou, PhD, Senior Director, Head of Computer Aided Detection and Diagnosis, Siemens Healthineers

Dr. Zhou studied Control Theory and Economics at Tsinghua University from 1988 to 1995, and received his PhD in computer vision and machine learning from University of Illinois at Urbana Champaign in 2002. In 2009, Dr. Zhou and team won the KDD Data Mining Practice Prize. In 2012, Dr. Zhou was awarded "Siemens Inventor of the Year" for his pioneering work in bringing ALPHA™ (Automatic Landmarking and Parsing of Human Anatomy), a suite of machine learning based anatomical pattern recognition algorithms, onto CT, MR, and PET-CT scanners and advanced medical image visualization, reading, and reporting solutions. Dr. Zhou holds more than 50 US and international patents.

De-Min Zhu, PhD, President and CEO, Curelong Group

De-Min obtained his Ph.D. degree in Physical Chemistry at Peking University, China. After 6 years of cross disciplinary scholar research at NIH and Harvard Medical School in biochemistry, biophysics, immunology, and cancer research, De-Min joined Merck and then Pfizer where he developed his career and leadership in biopharmaceutical formulation/process for vaccines, biologics, and drug delivery. With a VC investment, De-Min founded Cureport, Inc. in 2012 at Boston, MA. At Cureport De-Min invented and patented nPort™ nanotechnology that brought pharmaceutical a revolutionarily platform for liposome manufacturing from milligram to kilogram scales with adjustable particle size and robust reproducibility. In 2016, De-Min and his investors established Curelong (开瑞龙) Pharmaceutical Co. ltd. at Beijing, China and exclusively licensed Lymphcelle™ nanotechnology from Chinese Academy of Sciences with a 110 million RMB agreement. The two parties also collaboratively launched a Nanomedicine Research Center. Curelong recently signed several essential agreements with Beijing Daxing District to establish the first International Nanomedicine Base in the world. Daxing has provided Curelong with a new 9,000 m^2 building at its Bio-Pharmaceutical Industry Base to build up Curelong's nanomedicine pilot plant. De-Min serves as CEO for both Cureport and Curelong.

De-Min_published more than 30 peer-reviewed research articles. The equation he derived at Harvard Medical School for the determination of the two-dimensional binding constant (2D K_d) of laterally mobile cell surface proteins was widely cited in the literature as Zhu-Golan Equation in honoring De-Min's essential contribution to the study of the 2D binding of proteins.

Sponsors

新乡市平原示范区
Pingyuan Demonstration Zone of Xinxiang

Alliance PHARMA

CSPC 石药集团

PuraCap PHARMACEUTICAL

AMGEN

职库 | MY JOB TANK, INC.

CrownBio
CONNECTING SCIENCE TO PATIENTS

TCSci
TC Scientific Inc.

KELUN PHARMACEUTICAL

abpro

ALSTON & BIRD

ASCENDIA PHARMA

CLARITY · CONFIDENCE · CAPABILITY
FIP
Since 1995


GenScript
Make Research Easy


gsk
do more
feel better
live longer


冠昊科技园
GUANHAO INCUBATOR


Johnson & Johnson
Family of Companies


恒瑞
HENG RUI PHARMACEUTICALS


Sundia
We Accelerate Innovation!


药明康德
WuXi AppTec


华大基因
BGI


BIODURO


BPV
南京生物医药谷
NANJING BIOTECH
AND PHARMACEUTICAL VALLEY


BioSynergics
The Power of Synergy


Bristol-Myers Squibb


CURE port Inc.


FRONTAGE
YOUR DRUG DEVELOPMENT PARTNER


Ark Pharm, Inc.


Medicilon
Medicilon Inc.
Integrated Drug Discovery Services


MERCK
INVENTING FOR LIFE


ROCKLAND
antibodies & assays


sotio


AbHelix
ANTIBODY THERAPEUTICS THROUGH GENOMICS


DuaneMorris


ExCell Bio
依科赛生物


Morgan Stanley


纳微
Nano-Micro


WALVAX 沃森生物

Advertisement

Pingyuan Domestration District of Xinxiang, established in February 2010, has been included in the national key development area of the main function area in Henan and key area of the Zhengzhou–Luoyang–Xinxiang Self–dependent National Innovation Domestration Area seperately in 2014 and 2016. Covering 295 square kilometers, Pingyuan Domestration District is seperated from Zhengzhou by the Yellow River and connected with Zhengzhou by three bridges. It takes only 30 minutes from here to the center of Zhengzhou and Zhengzhou High–speed Railway Station and 40 minutes to Xinzheng International Airport, Zhengzhou Airport and Zhengzhou–Europe Freight Station. A convinient transport network is formed by G45 Expressway, Zhengzhou–Jiaozuo–Jincheng Expressway, 107 National Highway, 327 National Highway, Beijing–Guangzhou High–speed Railway, Zhengzhou–Jinan High–speed Railway and the Zhengzhou–Xinxiang Intercity Ligh Railway which is in planning. Pingyuan Demonstration District has set its development goals as participating in the new strategies of China and Henan Province, and being the bridgehead of Zhengzhou–Xinxiang integration, central city of Yellow River economic zone, pioneer of reform and opening–up, growth pole of Xinxiang' s development. Its three main industries which are healthcare industry, electronic information industry and high–end equipment manufacturing industry will be developed energetically.

Central Plains Biomedicine Industrial Park

Following the trend of economic globalization, and industrial gradient transfer law, Pingyuan Demonstration District establishes medical health as the leading industry, and sets up the investment attraction platform Central Plains Biomedicine Industry Park. With a planning area of 2.88 square kilometers, this Park aims to build six functional zones including Biomedicine Core Office Area, Biomedicine R&D Pilot Test Area, Biomedicine Industrialization Agglomeration Area, Biomedicine Outsourcing Area, Biomedicine Logistics Area, and Biomedicine Supporting Service Area. In April 2012, this Park was been listed as Henan–based strategic emerging industrial demonstration area by Henan Provincial Government.

Themed by "biomedicine", and focusing on blood products, vaccine products, biomedicine outsourcing, and biomedicine logistics service, Central Plains Biomedicine Industry Park prioritizes stem cell treatment, biological material, bioengineering agent, biological diagnosis reagent, and emphasizes the new–type therapeutic vaccine and monoclonal antibody drugs with proprietary intellectual property rights and huge market potentials.

Central Plains Biomedicine Industrial Park can provide various biomedicine enterprises with three public service platforms such as pilot test service, incubator service, and accelerator service.

Amgen Asia R&D Center, located in Shanghai, is an integral part of the world-leading biotechnology pioneer Amgen Inc., with a mission to serve patients in China and around the world.

We conduct cutting edge research in drug discovery against G-protein coupled receptors and translational medicine in immuno-oncology and cardiovascular diseases. We invest generously in nurturing next generation of life science leaders in China and host a MOHRSS-certified postdoctoral workstation. With our continued success and imminent expansion into brand new state-of-art R&D laboratories, we're looking to recruit a number of talented scientists who share our vision and passion for drug discovery in the following areas.

坐落于上海的安进亚洲研发中心，是全球领先的生物技术公司——安进公司的重要组成部分，以服务中国及全球患者为使命。

我们在针对G蛋白偶联受体的药物开发，免疫肿瘤学及心血管疾病中的转化医学方面开展前沿研究。同时投入大量人力及资金，培养生命科学领域的下一代领袖人才，并拥有“人力资源和社会保障部”认证的博士后工作站。在不断获得成功的基础上，我们进一步发展壮大，即将迁入全新的现代化研发实验室，我们正在以下领域招募数位才华横溢的科学家，诚意邀请您加入我们充满激情、志存高远的医药创新研发团队。

Medicinal Chemistry: Principal Scientist, Scientist, and Associate Scientists

- Ph. D in organic or medicinal chemistry with 0-8+ years of industry experience; for the Principal Scientist position, track records of project leading activities and relevant scientific publications are essential

Computational Chemistry: Associate Scientist

- Ph. D in computational chemistry with 0-3 years of industrial experience

Structural Biology Postdoc

- Ph. D graduate or postdoctoral fellow in protein crystallography; experience with membrane proteins is a plus

Translational Science: Biomarker postdoc

- preclinical biomarker research
- assay development and qualification
- genomic technologies including next generation sequencing, bioinformatics, transcriptomics and proteomics, molecular network analysis and modeling, common software toolkits for NGS analysis, scripting languages and mathematics tools, preferably in a Unix/Linux environment

Pharmacology: Scientist and Associate scientist

- Ph.D with 3-6 years of experience in receptor signaling pathway and animal model of diseases

Antibody discovery: Scientist and Associate scientist

- Ph.D with 3-6 years of experience in antibody expression, purification and characterization

The ClinPharm/Biostat postdoc

- computational PKPD modeling, simulation, and/or biostatistics of clinical data
- physiologically-based PK modeling and/or population PK analysis
- detailed knowledge of PK software and statistical analysis software

Biostatistics Manager

- Ph.D in (bio)statistics, preferably with 1-2 years of industrial experience

Biostatistical Programming Manager

- Master's degree in (bio)statistics with 5+ years of industrial experience in biostatistical programming

- The candidates are expected to work in a multi-disciplined environment and drive scientific and technical innovation collaboratively with other members of the groups, as well as within Amgen research community.
- Outstanding oral and written communication skills are required.
- Candidates with a strong entrepreneurial spirit, in line with Amgen's culture of innovation and pursuit of scientific excellence, are preferred.

HR Contact: Dake Shao (dshao@amgen.com)
R&D Site Contact: Bin Shi (bshi01@amgen.com)

BE VITAL

Vision

To build a fully enabled and globally integrated research and early development organization that delivers translational insights, new medicines and clinical POC for diseases that are important to China and global R&D.

Focus

Hepatitis B

Lung Cancer

Heme Malignancies



We are hiring

Director, Oncology Biology – Lung Cancer / Hematological Malignancy	Shanghai China
Clinical Pharmacology Leader	Shanghai/ Beijing, China
Senior Project Manager, PMO	Beijing/ Shanghai, China
China Compound Team Leader (CCTL) –Oncology / Neuroscience	Beijing/ Shanghai, China
Principal Scientist - Translational Research, Oncology	Shanghai, China
ASPAC Regulatory Policy Head, Medical Device	Beijing/ Shanghai, China
Director, Regulatory Affairs, pharmaceutical	Beijing/ Shanghai, China
Senior Manager, Global Clinical Operation Site Management	Beijing/ Shanghai, China

Contact us

Sofia GAO
Recruitment Manager
of J&J China
jgao21@its.jnj.com

CHINA R&D | Empowering Innovation Driving Growth

careers.jnj.com

janssen PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Map


EXECUTIVE BOARDROOM
ST DAVIDS
Centennial Ballroom III
Grand Ballroom
MALVERN
Haverford
Paoli
Centennial Ballroom II
Centennial Ballroom I
Main Entrance
BRYN MAWR
BERWYN
WAYNE
VILLANOVA
Frazer
GLADWYNE
Devon
Ardmore
STRAFFORD

大费城美中医药协会

热烈欢迎以下中国代表团参会交流并指导工作

中国医药企业管理协会

亚宝药业集团股份有限公司

杭州民生滨江制药有限公司

北京玉德未来投资有限公司

北京康辰药业股份有限公司

南京市江北新区管委会

南京江北新区产业技术研创园

南京高新区管委会

冠昊科技园

南京华威医药科技开发有限公司

新乡市平原示范区

方达医药技术（上海）有限公司

上海医药集团北京科园信海有限公司

北京大成律师事务所

国投创新投资有限公司

深圳信立泰药业股份有限公司

南京高新技术产业开发区管委会

南京生物医药谷建设发展有限公司

南京生物医药谷建设发展有限公司

南京正大天晴制药有限公司

CSPC 石药集团

www.cspc.com.hk

CSPC

COMPANY PROFILE

CSPC Pharmaceutical Group Limited ("CSPC") is a leading pharmaceutical group in China founded on Aug.21, 1997, currently there is approximately 22,000 staff and more than 30 subsidiary companies, the total assets is 4 billion US dollar, market value is 60 billion Hong Kong dollar. CSPC product portfolio covers oncology, antibiotics, cardiovascular and cerebrovascular, CNS, Metabolism, vitamins, etc.

CSPC has lunched 8 ANDA products in the US, and more than 70 products are in the R&D pipeline. At least 10 ANDAs are expected to be approved by USFDA every year from 2017. We have three FDA approved facilities for US market. The turnover of CSPC is 4 billion US dollar in 2016.

CSPC is specialized in R&D, production and sales, and has 180+ new drugs under development and more than 1500 R&D personnel. CSPC has mature liposome injection platform, Long-action patches platform and Long-action injection and Extended/Modified solid platform for its ANDA pipeline.

CSPC's mission is to develop good medicine for both China and the world. We create job opportunities not only in China, but also in the United States, CSPC employees all around the world are dedicated ourselves into the career that provide a healthier life for all mankind.